



(86) Date de dépôt PCT/PCT Filing Date: 2002/12/23	(51) Cl.Int. ⁷ /Int.Cl. ⁷ C12N 15/19, A61K 31/7088, A61K 48/00, A61K 39/395, A61K 38/22, A61K 38/19, C12N 15/16, C07K 16/24, C07K 16/26, C07K 14/52, C12Q 1/68, G01N 33/53
(87) Date publication PCT/PCT Publication Date: 2003/07/03	(71) Demandeur/Applicant: ARES TRADING S.A., CH
(85) Entrée phase nationale/National Entry: 2004/06/16	(72) Inventeurs/Inventors: FAGAN, RICHARD JOSEPH, GB; GUTTERIDGE, ALEX, GB; PHELPS, CHRISTOPHER BENJAMIN, GB; POWER, CHRISTINE, FR
(86) N° demande PCT/PCT Application No.: GB 2002/005885	(74) Agent: KIRBY EADES GALE BAKER
(87) N° publication PCT/PCT Publication No.: 2003/054012	
(30) Priorité/Priority: 2001/12/21 (0130720.6) GB	

(54) Titre : LEPTINES
(54) Title: LEPTIN PROTEINS

(57) **Abrégé/Abstract:**

This invention relates to novel protein INSP035, herein identified as a member of the four helical bundle cytokine family and to the use of this protein and the nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 03/054012 A3

(51) International Patent Classification⁷: **C07K 14/52**,
16/24, A61K 38/19, C12Q 1/68

(74) Agents: **GOODFELLOW, Hugh, Robin** et al.; Carp-
maels & Ransford, 43 Bloomsbury Square, London WC1A
2RA (GB).

(21) International Application Number: PCT/GB02/05885

(22) International Filing Date:
23 December 2002 (23.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0130720.6 21 December 2001 (21.12.2001) GB

(71) Applicant (*for all designated States except US*): **ARES
TRADING S.A.** [CH/CH]; Chateau de Vaumarcus,
CH-2028 Vaumarcus (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FAGAN, Richard,
Joseph** [US/GB]; Inpharmatica, 60 Charlotte Street, Lon-
don W1T 2NU (GB). **GUTTERIDGE, Alex** [GB/GB];
23 Broad Lane, Haslingfield, Cambridgeshire CB3 7JK
(GB). **PHELPS, Christopher, Benjamin** [GB/GB]; In-
pharmatica, 60 Charlotte Street, London W1T 2NU (GB).
POWER, Christine [GB/FR]; 10, rue des Jonquilles,
F-01710 Thoiry (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
20 November 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: LEPTIN PROTEINS

(57) Abstract: This invention relates to novel protein INSP035, herein identified as a member of the four helical bundle cytokine family and to the use of this protein and the nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.



WO 03/054012 A3

LEPTIN PROTEINS

This invention relates to novel protein INSP035 herein identified as herein identified as a secreted protein, in particular, as a member of the four helical bundle cytokine family, in particular, a member of the long chain cytokines family, most particularly, a leptin, and to
5 the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

BACKGROUND

10 The process of drug discovery is presently undergoing a fundamental revolution as the era of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions
15 to these protein sequences.

As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

20 Various institutions and commercial organisations are examining sequence data as they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

Introduction to Cytokines

25 Cytokines are a family of growth factors primarily secreted from leukocytes, and are messenger proteins that act as potent regulators capable of effecting cellular processes at sub-nanomolar concentrations. Interleukins, neurotrophins, growth factors, interferons and chemokines all define cytokine families that work in conjunction with cellular receptors to regulate cell proliferation and differentiation. Their size allows cytokines to

be quickly transported around the body and degraded when required. Their role in controlling a wide range of cellular functions, especially the immune response and cell growth has been revealed by extensive research over the last twenty years (Boppana, S.B (1996) Indian. J. Pediatr. 63(4):447-52). Cytokines, as for other growth factors, are
5 differentiated from classical hormones by the fact that they are produced by a number of different cell types rather than just one specific tissue or gland, and also effect a broad range of cells via interaction with specific high affinity receptors located on target cells.

All cytokine communication systems show both pleiotropy (one messenger producing multiple effects) and redundancy (each effect is produced by more than one messenger
10 (Tringali, G. et al. (2000) Therapie. 55(1):171-5; Tessarollo, L. (1998) Cytokine Growth Factor Rev. 9(2):125-137). An individual cytokine's effects on a cell can also be dependent on its concentration, the concentration of other cytokines, the temporal sequence of cytokines, and the internal state of the cell (cell cycle, presence of neighbouring cells, cancerous).

15 Although cytokines are typically small (under 200 amino acids) proteins they are often formed from larger precursors which are post-translationally spliced. This, in addition to mRNA alternative splicing pathways, give a wide spectrum of variants of each cytokine each of which may differ substantially in biological effect. Membrane and extracellular matrix associated forms of many cytokines have also been isolated (Okada-Ban, M. et al.
20 (2000) Int. J. Biochem. Cell Biol. 32(3):263-267; Atamas, S.P. (1997) Life Sci. 61(12):1105-1112).

Cytokines can be grouped into families, though most are unrelated. Categorisation is usually based on secondary structure composition, as sequence similarity is often very low. The families are named after the archetypal member e.g. IFN-like, IL2-like, IL1-like
25 and TNF-like (Zlotnik, A. et al. (2000) Immunity. 12(2):121-127).

Studies have shown cytokines are involved in many important reactions in multi-cellular organisms such as immune response regulation (Nishihira, J. (1998) Int. J. Mol. Med. 2(1):17-28), inflammation (Kim, P.K. et al. (2000) Surg. Clin. North. Am. 80(3):885-894), wound healing (Clark, R.A. (1991) J. Cell Biochem. 46(1):1-2), embryogenesis and
30 development, and apoptosis (Flad, H.D. et al. (1999) Pathobiology. 67(5-6):291-293).

Pathogenic organisms (both viral and bacterial) such as HIV and Kaposi's sarcoma-associated virus encode anti-cytokine factors as well as cytokine analogues, which allow them to interact with cytokine receptors and control the bodies immune response (Sozzani, S. et al. (2000) *Pharm. Acta. Helv.* 74(2-3):305-312; Aoki, Y. et al. (2000) *J. Hematother. Stem Cell Res.* 9(2):137-145). Virally encoded cytokines, virokines, have been shown to be required for pathogenicity of viruses due to their ability to mimic and subvert the host immune system.

Cytokines may be useful for the treatment, prevention and/or diagnosis of medical conditions and diseases which include immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, particularly human herpesvirus 5 (cytomegalovirus) infection.

It has been shown that the viral encoded cytokine, macrophage inhibitory protein-II is able to mediate selective recruitment of Th2-type cells and evasion from a cytotoxic immune response (Weber KS et al., (2001), *Eur. J. Immunol.* 2001 31(8):2458-66). These data provides evidence for an immunomodulatory role of vMIP-II in directing inflammatory cell recruitment away from a Th1-type towards a Th2-type response and thereby facilitating evasion from cytotoxic reactions. This protein could therefore be used to modulate diseases in which over-stimulation of the TH1-type immune response is implicated, such as irritable bowel syndrome. In another study, Kawamoto S. et al. (*Int.*

Immunol. 2001 13(5):685-94) presented results that indicate that vIL-10 may well be superior to cellular IL-10 in the treatment of autoimmune diabetes. These results indicate that viral encoded cytokines have potential therapeutic benefit beyond viral clearance alone.

- 5 Clinical use of cytokines has focused on their role as regulators of the immune system (Rodriguez, F.H. et al. (2000) Curr. Pharm. Des. 6(6):665-680) for instance in promoting a response against thyroid cancer (Schmutzler, C. et al. (2000) 143(1):15-24). Their control of cell growth and differentiation has also made cytokines anti-cancer targets (Lazar-Molnar, E. et al. (2000) Cytokine. 12(6):547-554; Gado, K. (2000) 24(4):195-
10 209). Novel mutations in cytokines and cytokine receptors have been shown to confer disease resistance in some cases (van Deventer, S.J. et al. (2000) Intensive Care Med. 26(Suppl 1):S98:S102). The creation of synthetic cytokines (muteins) in order to modulate activity and remove potential side effects has also been an important avenue of research (Shanafelt, A.B. et al. (1998) 95(16):9454-9458).
- 15 A subset of cytokines are the four- α -helix bundle cytokines, which are subdivided into short-chain and long-chain cytokines, as their helices comprise approximately 15 or 25 residues, respectively. Crystal structures have been determined for the long-chain four- α -helix bundle cytokines LIF, IL-6, CNTF, GH, granulocyte-colony stimulating factor (G-CSF), and leptin. Although exhibiting only a low degree of homology in their primary
20 structures, they show a high homology in their tertiary structures and in their functional receptor epitopes.

As described above, cytokine molecules have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as such identification of
25 novel cytokine molecules is highly relevant as they may play a role in or be useful in the development of treatments for the diseases identified above, as well as other disease states.

THE INVENTION

The invention is based on the discovery that the INSP035 protein is a secreted protein, in
30 particular, a member of the four helical bundle cytokine class, more particularly, a

member of the long chain cytokine family, and even more particularly, is a leptin.

In one embodiment of the first aspect of the invention, there is provided a polypeptide, which polypeptide:

- 5 (i) comprises the amino acid sequence as recited in SEQ ID NO: 2, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22 and/or SEQ ID NO:24;
- (ii) is a fragment thereof having secreted protein function, preferably four helical bundle cytokine function, more preferably long chain cytokine function, even more preferably, leptin function or having an antigenic determinant in common with the polypeptides of (i); or
- 10 (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this embodiment comprises the amino acid sequence recited in SEQ ID NO: 2. More preferably, the polypeptide consists of the amino acid sequence recited in SEQ ID NO: 2.

The polypeptide having the sequence recited in SEQ ID NO:18 is referred to hereafter as
15 "the INSP035 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:20 is referred to hereafter as "the INSP035 exon 2 polypeptide". Combining SEQ ID NO:18 and SEQ ID NO:20 produces the sequence recited in SEQ ID NO:22. SEQ ID NO:22 is referred to hereafter as the "predicted INSP035 polypeptide". SEQ ID NO:2 is referred to hereafter as "the cloned INSP035 polypeptide". INSP035 is also referred to in
20 the Examples section as IPAAA26841.

The predicted INSP035 nucleotide and polypeptide sequence (SEQ ID NOs:21 and 22 respectively) have been shown to be identical to part of the cloned full length INSP035 sequence (SEQ ID NO:1 gives a translation product with the polypeptide sequence of SEQ ID NO:2). The cloned sequence (SEQ ID NO:1) highlights three potential start
25 codons of which the cloned sequence (SEQ ID NO:1) is the sequence starting at the first potential start codon, SEQ ID NO:21 is the sequence starting at the second potential start codon and SEQ ID NO:23 is the sequence starting at the third potential start codon. The predicted INSP35 nucleotide sequence corresponds to the sequence starting at the second potential start codon (i.e. both have the sequence recited in SEQ ID NO21).

Preferably, the INSP035 polypeptides according to the first aspect of the invention function as polypeptide members of the four helical bundle cytokine class, in particular, as members of the long chain cytokine family, and more particularly, as leptins.

The term “members of the four helical bundle cytokine class” is well understood in the art and the skilled worker will readily be able to ascertain whether a polypeptide functions as a member of this class using one of a variety of assays known in the art. For example, assays may include measuring the effect on adipogenesis in preadipocytes in vitro. Another example is the assay disclosed in Kratzsch, J, Horm Res 2002; 57(3-4):127-32.

10 Polypeptides defined by sequence accession number Q9BTA0 on the SWISSPROT database, MGC10820 on the BLAST database, ABG12133 on the Derwent database are specifically excluded from the scope of the present invention.

In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention. Preferably, the purified nucleic acid molecule has the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the cloned
15 INSP035 polypeptide), SEQ ID NO:17 (encoding the INSP035 exon 1 polypeptide), SEQ ID NO:19 (encoding the INSP035 exon 2 polypeptide), SEQ ID NO:21 (the combination of SEQ ID NO:17 and SEQ ID NO:19 and thus encoding the INSP035 sequence starting at the second potential start codon), SEQ ID NO:23 (encoding the INSP035 sequence
20 starting at the third potential start codon) or is a redundant equivalent or fragment of any one of these sequences.

In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

25 In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention. Preferred vectors are those described in the Examples as pEAK12d-IPAAA26841long-6HIS (see Figure 8), pEAK12d-IPAAA26841-short-6HIS (see Figure 9), pEAK23s-sigptd-IPAAA26841-short (see Figure 10), pCR4 TOPO IPAAA26841 (see Figure 11) and
30 sigptdIPAAA26841s-6His (see Figure 14).

In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

In a sixth aspect, the invention provides a ligand which binds specifically to, and which preferably inhibits the secreted protein activity of a polypeptide of the first aspect of the invention. More preferably, the invention provides a ligand which binds specifically to and inhibits the cytokine activity of a polypeptide of the first aspect of the invention. Even more preferably, the invention provides a ligand which binds specifically to and which inhibits the long chain cytokine activity of a polypeptide of the first aspect of the invention. Most preferably, the invention provides a ligand which binds specifically to and which inhibits the leptin activity of a polypeptide of the first aspect of the invention.

In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide. Importantly, the identification of the function of the INSP035 exon polypeptides and the INSP035 polypeptides allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease.

In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis. These molecules may also be used in the manufacture of a medicament for the treatment of cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorders, infections and other pathological conditions. Preferably, the disorders include, but are not limited to immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis,

conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, more particularly human herpesvirus 5 (cytomegalovirus) infection.

In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out *in vitro*. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used

on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

5 In a tenth aspect, the invention provides for the use of the polypeptides of the first aspect of the invention as secreted protein molecules. Preferably, the polypeptides of the first aspect of the invention may be used as members of the four helical bundle cytokine class, in particular, as members of the long chain cytokine family, and more particularly, as leptins.

10 In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

15 In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or
20 treatment of a disease, such as cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorders, infections and other pathological conditions. In particular, the diseases include, but are not limited to immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple
25 sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive
30 pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological

disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, 5 AIDS, AIDS related complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, even more particularly human herpesvirus 5 (cytomegalovirus) infection.

In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, 10 or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the 15 invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, 20 nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes and ligands, such as antibodies.

In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of 25 the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease.

A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited 30 to the particular methodology, protocols, cell lines, vectors and reagents described. It is

also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims.

5 Standard abbreviations for nucleotides and amino acids are used in this specification.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

Such techniques are explained fully in the literature. Examples of particularly suitable
10 texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and
15 Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987)
20 Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e.
25 peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-,
30 pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that

is employed for purification of the mature polypeptide sequence.

The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in
5 purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Polypeptides may contain amino acids other than the 20 gene-encoded amino acids,
10 modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential
15 modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of
20 pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the
25 amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

The modifications that occur in a polypeptide often will be a function of how the
30 polypeptide is made. For polypeptides that are made recombinantly, the nature and extent

of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.

- 5 The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.
- 10 The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSP035 exon polypeptides and/or to the INSP035 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at
- 15 any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing.
- 20 Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).
- 25 Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INSP035 exon polypeptides and of the INSP035 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are
- 30 substituted with a conserved or non-conserved amino acid residue (preferably a

conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr.

5 Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions.

10 Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group;

Typically, greater than 80% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with INSP035, exon
15 polypeptides or the INSP035 polypeptides, or with active fragments thereof, of greater than 80%. More preferred polypeptides have degrees of identity of greater than 90%, 95%, 98% or 99%, respectively.

The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural
20 alignment. For example, the Inpharmatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium search database may be used (see co-pending PCT patent application PCT/GB01/01105) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSP035 exon polypeptides or the INSP035 polypeptides, are predicted to have four
25 secreted protein activity, preferably cytokine activity, more preferably, long chain cytokine activity, even more preferably, leptin activity, by virtue of sharing significant structural homology with the INSP035 exon polypeptides or the INSP035 polypeptide sequences. By "significant structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and
30 above.

The polypeptides of the first aspect of the invention also include fragments of the INSP035 exon polypeptides and the INSP035 polypeptides and fragments of the functional equivalents of these polypeptides, provided that those fragments retain secreted protein activity, in particular, four helical bundle cytokine activity, more particularly, long chain cytokine activity and even more particularly, leptin activity, or have an antigenic determinant in common with these polypeptides.

As used herein, the term "fragment" refers to a polypeptide having an amino acid sequence that is the same as part, but not all, of the amino acid sequence of the INSP035, polypeptides or one of its functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre - and/or pro- polypeptide region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to

fragments thereof, such as Fab, F(ab')₂ and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985).

Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 84, 3439 (1987)), may also be of use.

The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, *Nature*, 321, 522 (1986); Verhoeyen *et al.*, *Science*, 239, 1534 (1988); Kabat *et al.*, *J. Immunol.*, 147, 1709 (1991); Queen *et al.*, *Proc. Natl*

Acad. Sci. USA, 86, 10029 (1989); Gorman *et al.*, Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson *et al.*, Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of
5 a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen-binding domains, each domain being directed against a
10 different epitope.

Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348,
15 552-554; Marks, J. *et al.*, (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays,
20 radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode the polypeptide sequences recited in SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22 and SEQ ID NO:24 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least
25 n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or
30 more).

The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing purposes).

5 Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation
10 from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

15 The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones ,and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers
20 solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. *et al.* (1993) *Anticancer Drug Des.* 8:53-63).

A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:2 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:1. A
25 nucleic acid molecule which encodes the polypeptide of SEQ ID NO:18 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:17. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:20 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:19. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:22 may be identical to the
30 coding sequence of the nucleic acid molecule shown in SEQ ID NO:21. A nucleic acid

molecule which encodes the polypeptide of SEQ ID NO:24 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:23.

These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes a polypeptide of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22 and SEQ ID NO:24. Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring variant such as a naturally-occurring allelic variant, or the molecule may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.

The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by

random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth.

Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991).

The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction

temperature; time of hybridization; agitation; agents to block the non specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook *et al.* [supra]).

The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al.* [supra]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation reaction being carried out at 35°C (see Sambrook *et al.* [supra]). Preferably, the conditions used for hybridization are those of high stringency.

Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the INSP035 polypeptides (SEQ ID NO:22 [equivalent to SEQ ID NO:18, and SEQ ID NO:20 combined], SEQ ID NO:2 or SEQ ID NO:24) and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecules having the sequence produced by combining SEQ ID NO:17 and SEQ ID NO:19 (equivalent to SEQ ID NO:21), SEQ ID NO:1, SEQ ID NO:23 or a nucleic acid molecule that is complementary

thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP035 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INSP035 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP035 polypeptides is to probe a genomic or cDNA library with a natural or artificially-designed probe using standard procedures that are

recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel *et al.* (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23) are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the MarathonTM technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve

unknown sequences is that of Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

- 5 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for
10 extension of sequence into 5' non-transcribed regulatory regions.

In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to
15 the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins
20 University Welch Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene
25 discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

The nucleic acid molecules of the present invention are also valuable for tissue
30 localisation. Such techniques allow the determination of expression patterns of the

polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the polypeptide in the organism. In addition, comparative studies of the normal expression
5 pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

Gene silencing approaches may also be undertaken to down-regulate endogenous expression of a gene encoding a polypeptide of the invention. RNA interference (RNAi)
10 (Elbashir, SM *et al.*, Nature 2001, 411, 494-498) is one method of sequence specific post-transcriptional gene silencing that may be employed. Short dsRNA oligonucleotides are synthesised *in vitro* and introduced into a cell. The sequence specific binding of these dsRNA oligonucleotides triggers the degradation of target mRNA, reducing or ablating target protein expression.

15 Efficacy of the gene silencing approaches assessed above may be assessed through the measurement of polypeptide expression (for example, by Western blotting), and at the RNA level using TaqMan-based methodologies.

The vectors of the present invention comprise nucleic acid molecules of the invention and may be cloning or expression vectors. The host cells of the invention, which may be
20 transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in
25 detail by Sambrook *et al* (*supra*) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The
30 appropriate nucleotide sequence may be inserted into an expression system by any of a

variety of well-known and routine techniques, such as, for example, those described in Sambrook *et al.*, (supra). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide
5 is transcribed into RNA in the transformed host cell.

Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40,
10 vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

15 Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco
20 mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory
25 manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, [supra]. Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook *et al.*, 1989 [supra]; Ausubel *et al.*, 1991 [supra]; Spector,
30 Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be

transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system.

The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for
5 secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that
10 allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers,
15 promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible
20 promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences)
25 may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

An expression vector is constructed so that the particular nucleic acid coding sequence is
30 located in the vector with the appropriate regulatory sequences, the positioning and

orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the
5 sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences
10 and an appropriate restriction site.

For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a
15 separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture
20 techniques appropriate to the cell type.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes
25 melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and are
30 described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin

No. 1555 (1987). Particularly suitable host cells for use in this system include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells.

There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those
5 described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30, 3861-3863 (1991).

In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the
10 transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells.

15 Examples of particularly suitable host cells for fungal expression include yeast cells (for example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy,
20 I. *et al.* (1980) *Cell* 22:817-23) genes that can be employed in tk- or *aprt*[±] cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); *npt*, which
25 confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al* (1981) *J. Mol. Biol.* 150:1-14) and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of

interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence
5 encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of
10 procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or
15 quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) *Serological Methods, a Laboratory Manual*, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) *J. Exp. Med.*, 158, 1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing
20 labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art,
25 are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)).

30 Suitable reporter molecules or labels, which may be used for ease of detection, include

radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further
5 aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant cell cultures by well-
10 known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be
15 employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble
20 proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for
25 Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC
30 (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992),

Prot. Exp. Purif. 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; DNA Cell Biol. 12:441-453).

- 5 If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered
10 in order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the
15 invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

Agonist or antagonist compounds may be isolated from, for example, cells, cell-free
20 preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991).

Compounds that are most likely to be good antagonists are molecules that bind to the
25 polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of
30 the polypeptide is prevented.

The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to
5 observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the
10 presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.

A preferred method for identifying an agonist or antagonist compound of a polypeptide of the present invention comprises:

- 15 (a) contacting a cell expressing on the surface thereof the polypeptide according to the first aspect of the invention, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
- 20 (b) determining whether the compound binds to and activates or inhibits the polypeptide by measuring the level of a signal generated from the interaction of the compound with the polypeptide.

A further preferred method for identifying an agonist or antagonist of a polypeptide of the invention comprises:

- 25 (a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
- (b) determining whether the compound binds to and activates or inhibits the

polypeptide by comparing the level of a signal generated from the interaction of the compound with the polypeptide with the level of a signal in the absence of the compound.

In further preferred embodiments, the general methods that are described above may
5 further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled ligand for the polypeptide.

In another embodiment of the method for identifying agonist or antagonist of a polypeptide of the present invention comprises:

determining the inhibition of binding of a ligand to cells which have a polypeptide of the
10 invention on the surface thereof, or to cell membranes containing such a polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand bound to the polypeptide. A compound capable of causing reduction of binding of a ligand is considered to be an agonist or antagonist. Preferably the ligand is labelled.

15 More particularly, a method of screening for a polypeptide antagonist or agonist compound comprises the steps of:

- (a) incubating a labelled ligand with a whole cell expressing a polypeptide according to the invention on the cell surface, or a cell membrane containing a polypeptide of the invention,
- 20 (b) measuring the amount of labelled ligand bound to the whole cell or the cell membrane;
- (c) adding a candidate compound to a mixture of labelled ligand and the whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium;
- (d) measuring the amount of labelled ligand bound to the whole cell or the cell
25 membrane after step (c); and
- (e) comparing the difference in the labelled ligand bound in step (b) and (d), such that the compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

The polypeptides may be found to modulate a variety of physiological and pathological processes in a dose-dependent manner in the above-described assays. Thus, the “functional equivalents” of the polypeptides of the invention include polypeptides that exhibit any of the same modulatory activities in the above-described assays in a dose-
5 dependent manner. Although the degree of dose-dependent activity need not be identical to that of the polypeptides of the invention, preferably the “functional equivalents” will exhibit substantially similar dose-dependence in a given activity assay compared to the polypeptides of the invention.

In certain of the embodiments described above, simple binding assays may be used, in
10 which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this
15 manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using
20 monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured.

25 Assay methods that are also included within the terms of the present invention are those that involve the use of the genes and polypeptides of the invention in overexpression or ablation assays. Such assays involve the manipulation of levels of these genes/polypeptides in cells and assessment of the impact of this manipulation event on the physiology of the manipulated cells. For example, such experiments reveal details of
30 signaling and metabolic pathways in which the particular genes/polypeptides are

implicated, generate information regarding the identities of polypeptides with which the studied polypeptides interact and provide clues as to methods by which related genes and proteins are regulated.

Another technique for drug screening which may be used provides for high throughput
5 screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be
10 detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a
15 radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be
20 used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

The invention also includes a screening kit useful in the methods for identifying agonists,
25 antagonists, ligands, receptors, substrates, enzymes, that are described above.

The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

The invention also provides pharmaceutical compositions comprising a polypeptide,
30 nucleic acid, ligand or compound of the invention in combination with a suitable

pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention.

10 The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs.

15 The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.

Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts
5 such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may additionally
10 contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

15 Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-
20 arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or
25 suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion.
30 Dosage treatment may be a single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.* (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated *in situ* from expression *in vivo*.

In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin.

Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the
5 ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified bases.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5'
10 and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and
15 uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition.
20 Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the
25 inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in*
30 *vivo* gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising

polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

10 The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, Nature, 324, 163-166 (1986); Bej, *et al.*, Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer *et al.*, J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of:

a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;

b) contacting a control sample with said probe under the same conditions used in step a);

5 c) and detecting the presence of hybrid complexes in said samples;

wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

A further aspect of the invention comprises a diagnostic method comprising the steps of:

a) obtaining a tissue sample from a patient being tested for disease;

10 b) isolating a nucleic acid molecule according to the invention from said tissue sample;
and

c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

To aid the detection of nucleic acid molecules in the above-described methods, an
15 amplification step, for example using PCR, may be included.

Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be distinguished from
20 mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion
25 corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

Such diagnostics are particularly useful for prenatal and even neonatal testing.

Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in situ* hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562 (1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of

questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science (1996), Vol 274, pp 610-613).

In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al.*); Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14:
5 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619).

Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process.

The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized

10 on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to

arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array,

15 such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

20 In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for
25 instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

Assay techniques that can be used to determine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding
30 assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a

diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

5 Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various
10 methods, such as by photometric means.

Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes
15 may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of
20 reporter molecules known in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to
25 monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

(a) a nucleic acid molecule of the present invention;

(b) a polypeptide of the present invention; or

(c) a ligand of the present invention.

In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

To detect polypeptide according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

Such kits will be of use in diagnosing a disease or susceptibility to disease, particularly cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorders, infections and other pathological conditions. Preferably, these disorders include, but are not limited to immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related

complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, even more preferably, human herpesvirus 5 (cytomegalovirus) infection.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference INSP035 polypeptides.

It will be appreciated that modification of detail may be made without departing from the scope of the invention.

Brief description of the Figures

Figure 1: Results from Inpharmatica Genome Threader query using combined SEQ ID NO:18 and SEQ ID NO:20 polypeptide sequences (equivalent to SEQ ID NO:22).

Figure 2: Alignment generated by Inpharmatica Genome Threader between combined SEQ ID NO:18 and SEQ ID NO:20 polypeptide sequence (equivalent to SEQ ID NO:22) and closest related structure.

Figure 3: Predicted nucleotide sequence of IPAAA26841 (comprising SEQ ID NO:21) with translation (SEQ ID NO:22).

Figure 4: Nucleotide sequence with translation of PCR product cloned using primer 26841-CP1 and 26841-CP1.

Figure 5: Map of pCR4 blunt-TOPO-IPAAA26841.

Figure 6: Map of expression vector pEAK12d.

Figure 7: Map of Gateway vector pDONR201.

Figure 8: Map of pEAK12d-IPAAA26841long-6HIS.

Figure 9: Map of plasmid pEAK12d-IPAAA26841-short-6HIS.

Figure 10: Map of plasmid pEAK23s-sigptd-IPAAA26841-short

Figure 11: Nucleotide sequence of PCR4 TOPO IPAAA26841.

Figure 12: Nucleotide sequence of pEAK12D-IPAAA26841long-6His

Figure 13: Nucleotide sequence of pEAK12D-IPAAA26841-6His.

Figure 14: Nucleotide sequence of sigptdIPAAA26841s-6His.

Figure 15: The NCBI-NR results for INSP035 polypeptide (SEQ ID NO:2) showing a 100% match over part of the sequence to a hypothetical protein (NP_116037), i.e. there is no annotated function. The alignments to NP_116037 and p17257 are also shown.

5 Figure 16: The NCBI-month-aa/NCBI-month-nt results for INSP035 polypeptide (SEQ ID NO:2).

Figure 17: The NCBI-nt results for INSP035 polypeptide (SEQ ID NO:2).

Figure 18: The NCBI-est results for INSP035 polypeptide (SEQ ID NO:2).

Examples

10 Example 1: INSP035

The polypeptide sequence derived from combining SEQ ID NO:18 and SEQ ID NO:20 (equivalent to SEQ ID NO:22) which represent the translation of consecutive exons from INSP035 was used as a query in the Inpharmatica Genome Threader tool against protein structures present in the PDB database. The top match is the structure of a four helical
15 bundle cytokine family member. The top match aligns to the query sequence with a Genome Threader confidence of 79% (Figure 1). Figure 2 shows the alignment of the INSP035 query sequence to the sequence of human obesity protein (leptin) (PDB-1ax8) a member of the four helical bundle cytokine family (Zhang *et al*, Nature. 1997 May 8;387(6629):206-9). Note that the INSP035 polypeptide sequence is referred to as “User-
20 Seq” in Figure 2. Members of the four helical bundle cytokine family of proteins are of significant therapeutic importance.

1. Cloning of IPAAA26841

1.1 cDNA libraries

Human cDNA libraries (in bacteriophage lambda (λ) vectors) were purchased from
25 Stratagene or Clontech or prepared at the Serono Pharmaceutical Research Institute in λ ZAP or λ GT10 vectors according to the manufacturer's protocol (Stratagene). Bacteriophage λ DNA was prepared from small scale cultures of infected *E.coli* host

strain using the Wizard Lambda Preps DNA purification system according to the manufacturer's instructions (Promega, Corporation, Madison WI.) The list of libraries and host strains used is shown in Table I. Eight pools (A-H) of five different libraries (100 ng/μl phage DNA) or phage DNA from individual libraries were used in subsequent PCR reactions.

1.2 PCR of virtual cDNAs from phage library DNA

A cDNA containing the full coding sequence of INSP035 (IPAAA26841; Figure 3) was obtained as a PCR amplification product of 511 bp using gene specific cloning primers (26841-CP1 and 26841-CP2, Figure 3 and Table II). The PCR was performed in a final volume of 50 μl containing 1X AmpliTaq™ buffer, 200 μM dNTPs, 50 pmoles each of cloning primers, 2.5 units of AmpliTaq™ (Perkin Elmer) and 100 ng of each phage library pool DNA using an MJ Research DNA Engine, programmed as follows: 94 °C, 1 min; 40 cycles of 94 °C, 1 min, x °C, and y min and 72 °C, (where x is the lowest $T_m - 5$ °C and $y = 1$ min per kb of product); followed by 1 cycle at 72 °C for 7 min and a holding cycle at 4 °C.

The amplification products were visualized on 0.8 % agarose gels in 1 X TAE buffer (Invitrogen) and PCR products migrating at the predicted molecular mass were purified from the gel using the Wizard PCR Preps DNA Purification System (Promega). PCR products eluted in 50 μl of sterile water were either subcloned directly or stored at -20 °C.

1.3 Gene specific cloning primers for PCR

Pairs of PCR primers having a length of between 18 and 25 bases were designed for amplifying the full length and partial sequence of the virtual cDNA using Primer Designer Software (Scientific & Educational Software, PO Box 72045, Durham, NC 27722-2045, USA). PCR primers were optimized to have a T_m close to 55 ± 10 °C and a GC content of 40-60%. Primers were selected which had high selectivity for the target sequence INSP035 (IPAAA26841) (little or no non specific priming).

1.4 Subcloning of PCR Products

PCR products were subcloned into the topoisomerase I modified cloning vector (pCR4blunt TOPO) using the TA cloning kit purchased from the Invitrogen Corporation using the conditions specified by the manufacturer. Briefly, 4 µl of gel purified PCR product from the human library pool N amplification was incubated for 15 min at room temperature with 1 µl of TOPO vector and 1 µl salt solution. The reaction mixture was then transformed into *E. coli* strain TOP10 (Invitrogen) as follows: a 50 µl aliquot of One Shot TOP10 cells was thawed on ice and 2 µl of TOPO reaction was added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42 °C for exactly 30 s. Samples were returned to ice and 250 µl of warm SOC media (room temperature) was added. Samples were incubated with shaking (220 rpm) for 1 h at 37 °C. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100 µg/ml) and incubated overnight at 37 °C. Ampicillin resistant colonies containing cDNA inserts were identified by colony PCR.

1.5 Colony PCR

Colonies were inoculated into 50 µl sterile water using a sterile toothpick. A 10 µl aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 µl as described above, except the primers used were T3 and T7. The cycling conditions were as follows: 94 °C, 2 min; 30 cycles of 94 °C, 30 sec, 47 °C, 30 sec and 72 °C for 1 min); 1 cycle, 72 °C, 7 min. Samples were then maintained at 4 °C (holding cycle) before further analysis.

PCR reaction products were analyzed on 1 % agarose gels in 1 X TAE buffer. Colonies which gave the expected PCR product size (511 bp cDNA + 106 bp due to the multiple cloning site or MCS) were grown up overnight at 37 °C in 5 ml L-Broth (LB) containing ampicillin (100 µg /ml), with shaking at 220 rpm at 37 °C.

1.6 Plasmid DNA preparation and Sequencing

Miniprep plasmid DNA was prepared from 5 ml cultures using a Qiaprep Turbo 9600 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460) according to the manufacturer's instructions. Plasmid DNA was eluted in 100 µl of sterile water. The DNA concentration was measured using an Eppendorf BO photometer. Plasmid DNA (200-500 ng) was subjected to DNA sequencing with T7 primer and T3

primer using the BigDyeTerminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer. The sequence of the cloned cDNA fragment is shown in figure 4.

2. Construction of plasmids for expression of INSP035 (IPAAA26841) in HEK293/EBNA cells.

A pCRII-TOPO clone containing the full coding sequence (ORF) of INSP035 (IPAAA26841) identified by DNA sequencing (Figure 5; plasmid ID. 12130) was then used to subclone the insert into the mammalian cell expression vector pEAK12d (figure 6) using the GatewayTM cloning methodology (Invitrogen).

2.1 Generation of Gateway compatible INSP035 (IPAAA26841) ORF fused to an in-frame 6HIS tag sequence.

The coding sequence INSP035 (IPAAA26841) contains several potential initiating methionines. We therefore decided to generate 2 expression clones using the first and second methionines in the longest ORF, designated IPAAA26841-long and IPAAA26841- short form respectively.

The Gateway cloning process involves a two step PCR reaction which generates the ORF of INSP035 (IPAAA26841) flanked at the 5' end by an attB1 recombination site and Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible cDNA). To generate IPAAA26841-long, the first PCR reaction (in a final volume of 50 µl) contains: 25 ng of pCR II TOPO-IPAAA26841 (plasmid 12130, Figure 5), 2 µl dNTPs (5mM), 5 µl of 10X Pfx polymerase buffer, 0.5 µl each of gene specific primer (100 µM) (26841 long EX1 (forward) and 26841 EX2 (reverse) and 0.5 µl Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95°C for 2 min, followed by 12 cycles of 94 °C, 15 sec and 68°C for 30 sec. PCR products were purified directly from the reaction mixture using the Wizard PCR prep DNA purification system (Promega) according to the manufacturer's instructions. To

generate IPAAA26841-short form, the first PCR reaction was identical except that the PCR primers used were: 26841 short EX1 and 26841 EX2.

The second PCR reaction (in a final volume of 50 μ l) contained 10 μ l purified PCR product, 2 μ l dNTPs (5 mM), 5 μ l of 10X Pfx polymerase buffer, 0.5 μ l of each Gateway conversion primer (100 μ M) (GCP forward and GCP reverse) and 0.5 μ l of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 95 $^{\circ}$ C for 1 min; 4 cycles of 94 $^{\circ}$ C, 15 sec; 45 $^{\circ}$ C, 30 sec and 68 $^{\circ}$ C for 3.5 min; 25 cycles of 94 $^{\circ}$ C, 15 sec; 55 $^{\circ}$ C, 30 sec and 68 $^{\circ}$ C, 3.5 min. PCR products were purified as described above.

2.2 Subcloning of Gateway compatible INSP035 (IPAAA26841) ORF into Gateway entry vector pDONR201 and expression vector pEAK12d

The second stage of the Gateway cloning process involves subcloning of the Gateway modified PCR product into the Gateway entry vector pDONR201 (Invitrogen, figure 7) as follows: 5 μ l of purified PCR product is incubated with 1.5 μ l pDONR201 vector (0.1 μ g/ μ l), 2 μ l BP buffer and 1.5 μ l of BP clonase enzyme mix (Invitrogen) at RT for 1 h. The reaction was stopped by addition of proteinase K (2 μ g) and incubated at 37 $^{\circ}$ C for a further 10 min. An aliquot of this reaction (2 μ l) was transformed into *E. coli* DH10B cells by electroporation using a Biorad Gene Pulser. Transformants were plated on LB-kanamycin plates. Plasmid mini-prep DNA was prepared from 1-4 of the resultant colonies using Wizard Plus SV Minipreps kit (Promega), and 1.5 μ l of the plasmid eluate was then used in a recombination reaction containing 1.5 μ l pEAK12d vector (figure 6) (0.1 μ g / μ l), 2 μ l LR buffer and 1.5 μ l of LR clonase (Invitrogen) in a final volume of 10 μ l. The mixture was incubated at RT for 1 h, stopped by addition of proteinase K (2 μ g) and incubated at 37 $^{\circ}$ C for a further 10 min. An aliquot of this reaction (1 μ l) was used to transform *E. coli* DH10B cells by electroporation.

Clones containing the correct insert were identified by performing colony PCR as described above except that pEAK12d primers (pEAK12d F and pEAK12d R) were used for the PCR. Plasmid mini prep DNA was isolated from clones containing the correct insert using a Qiaprep Turbo 9600 robotic system (Qiagen) or manually using a Wizard

Plus SV minipreps kit (Promega) and sequence verified using the pEAK12d F and pEAK12d R primers.

CsCl gradient purified maxi-prep DNA of plasmid pEAK12d-IPAAA26841 long 6HIS (plasmid ID number 12148, figure 8) and plasmid pEAK12d-IPAAA26841-short 6HIS (plasmid ID number 12686, figure 9) were prepared from a 500 ml culture of each sequence verified clone (Sambrook J. et al., in Molecular Cloning, a Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press), resuspended at a concentration of 1 µg/µl in sterile water and stored at -20 C.

2.3 Generation of Gateway compatible IPAAA26841 short ORF containing an in frame signal sequence from IL-12p40 at the 5' end, and an in-frame 6HIS tag sequence at the 3' end.

The predicted sequence of INSP035 (IPAAA26841) does not contain an obvious signal peptide sequence at the 5' end of the coding sequence. Therefore, in order to facilitate secretion of the expressed cDNA in the HEK293/EBNA system, we engineered a version of the INSP035 (IPAAA26841) coding sequence, which contained a signal sequence derived from IL-12p40 (Swissprot P29460). The IL-12p40 signal sequence encodes a 22 amino acids signal peptide with the sequence MCHQQLVISW FSLVFLASPL VA. The signal peptide is cleaved between Ala22 and Ile23 in the precursor protein. The IL-12p40 signal sequence was added in two sequential PCR reactions to the 5' end of the IPAAA26841-short form coding sequence. In the first PCR, the coding sequence for amino acids 11-22 of IL-12p40 is added to the 5' end of IPAAA26841. In order to ensure that the signal peptide cleavage site is maintained, the ATG start codon of IPAAA26841 is mutated to ATA (Met-Ile) in the PCR primer. In the 2nd PCR, the coding sequence of amino acids 1-10 is added. The resultant PCR product is then made Gateway cloning system compatible in a third PCR reaction by addition of attB1 and attB2 recombination sites at the 5' and 3' ends respectively.

To generate the IL12p40 (1-22) - IPAAA26841-short fusion, the first PCR reaction (in a final volume of 50 µl) contains: 25 ng of pCR II TOPO-IPAAA26841 (plasmid 12686 and Figure 9), 2 µl dNTPs (5mM), 5µl of 10X Pfx polymerase buffer, 0.5 µl each of gene specific primer (100 µM) (26841-SP1 and 26841-EX2) and 0.5 µl Platinum Pfx DNA

polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95°C for 2 min, followed by 10 cycles of 94 °C, 15 sec and 68°C for 30 sec. PCR products were purified directly from the reaction mixture using the Wizard PCR prep DNA purification system (Promega) according to the manufacturer's instructions. The

5 second PCR reaction (in a final volume of 50 µl) contained 10 µl purified PCR product, 2 µl dNTPs (5 mM), 5 µl of 10X Pfx polymerase buffer, 0.5 µl of primers (SP2 and GCP reverse) (100 µM each) and 0.5 µl of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: an initial denaturing step of 95°C for 2 min, followed by 10 cycles of 94 °C, 15 sec and 68°C for 30 sec. PCR products were purified directly from the

10 reaction mixture using the Wizard PCR prep DNA purification system (Promega) according to the manufacturer's instructions. For the third PCR reaction, the primers used were SP3 and GCPR (100 µM each) and 0.5 µl of Platinum Pfx DNA polymerase. The reaction conditions were 95 °C for 1 min; 4 cycles of 94 °C, 15 sec; 45 °C, 30 sec and 68 °C for 3.5 min; 25 cycles of 94 °C, 15 sec; 55 °C , 30 sec and 68 °C, 3.5 min. PCR

15 products were purified as described above. The PCR product was then subcloned as described in section 2.2 to yield expression vector pEAK12d-sigptd-IPAAA26841 short (plasmid ID. 12737, figure 10)

2.4 Construction of expression vector pEAK12d

The vector pEAK12d is a Gateway Cloning System compatible version of the

20 mammalian cell expression vector pEAK12 (purchased from Edge Biosystems) in which the cDNA of interest is expressed under the control of the human EF1α promoter. pEAK12d was generated as described below:

pEAK12 was digested with restriction enzymes HindIII and NotI, made blunt ended with Klenow (New England Biolabs) and dephosphorylated using calf-intestinal alkaline

25 phosphatase (Roche). After dephosphorylation, the vector was ligated to the blunt ended Gateway reading frame cassette C (Gateway vector conversion system, Invitrogen cat no. 11828-019) which contains AttR recombination sites flanking the ccdB gene and chloramphenicol resistance, and transformed into *E.coli* DB3.1 cells (which allow propagation of vectors containing the ccdB gene). Mini prep DNA was isolated from

30 several of the resultant colonies using a Wizard Plus SV Minipreps kit (Promega) and

digested with AseI / EcoRI to identify clones yielding a 670 bp fragment, indicating that the cassette had been inserted in the correct orientation. The resultant plasmid was called pEAK12d (figure 6).

3. Identification of cDNA libraries/templates containing INSP035 (IPAAA26841)

PCR products obtained with 26841-CP1 and 26841-CP2 and migrating at the correct size (511 bp) were identified in the CFPoc-1, SHSYSY and U373 cells, and retina and bladder cDNA libraries as well in Pool C (fetal lung, fetal kidney, fetal liver, bone marrow and placenta) and Pool B (fetal brain, ovary, pituitary and placenta). The plasmid map of the cloned PCR product (pCR4 blunt-TOPO-IPAAA26841) (plasmid ID.12130), is shown in Figure 5.

Table I Human cDNA libraries

Library	Tissue/cell source	Vector	Host strain	Supplier	Cat. no.
1	human fetal brain	Zap II	XL1-Blue MRF'	Stratagene	936206
2	human ovary	GT10	LE392	Clontech	HL1098a
3	human pituitary	GT10	LE392	Clontech	HL1097a
4	human placenta	GT11	LE392	Clontech	HL1075b
5	human testis	GT11	LE392	Clontech	HL1010b
6	human substantia nigra	GT10	LE392	in house	
7	human fetal brain	GT10	LE392	in house	
8	human cortex brain	GT10	LE392	in house	
9	human colon	GT10	LE392	Clontech	HL1034a
10	human fetal brain	GT10	LE392	Clontech	HL1065a
11	human fetal lung	GT10	LE392	Clontech	HL1072a
12	human fetal kidney	GT10	LE392	Clontech	HL1071a
13	human fetal liver	GT10	LE392	Clontech	HL1064a
14	human bone marrow	GT10	LE392	Clontech	HL1058a
15	human peripheral blood monocytes	GT10	LE392	Clontech	HL1050a
16	human placenta	GT10	LE392	in house	
17	human SHSYSY	GT10	LE392	in house	
18	human U373 cell line	GT10	LE392	in house	
19	human CFPoc-1 cell line	Uni Zap	XL1-Blue MRF'	Stratagene	936206
20	human retina	GT10	LE392	Clontech	HL1132a
21	human urinary bladder	GT10	LE392	in house	
22	human platelets	Uni Zap	XL1-Blue MRF'	in house	
23	human neuroblastoma Kan + TS	GT10	LE392	in house	

24	human bronchial smooth muscle	GT10	LE392	in house	
25	human bronchial smooth muscle	GT10	LE392	in house	
26	human Thymus	GT10	LE392	Clontech	HL1127a
27	human spleen 5' stretch	GT11	LE392	Clontech	HL1134b
28	human peripheral blood monocytes	GT10	LE392	Clontech	HL1050a
29	human testis	GT10	LE392	Clontech	HL1065a
30	human fetal brain	GT10	LE392	Clontech	HL1065a
31	human substantia nigra	GT10	LE392	Clontech	HL1093a
32	human placenta#11	GT11	LE392	Clontech	HL1075b
33	human Fetal brain	GT10	LE392	Clontech	custom
34	human placenta #59	GT10	LE392	Clontech	HL5014a
35	human pituitary	GT10	LE392	Clontech	HL1097a
36	human pancreas #63	Uni Zap XR	XL1-Blue MRF'	Stratagene	937208
37	human placenta #19	GT11	LE392	Clontech	HL1008
38	human liver 5'stretch	GT11	LE392	Clontech	HL1115b
39	human uterus	Zap-CMV XR	XL1-Blue MRF'	Stratagene	980207
40	human kidney large-insert cDNA library	TriplEx2	XL1-Blue	Clontech	HL5507u

Table II

IPAAA26841 Cloning primers

Primer	Sequence (5' -3')
26841-CP1	CAC CTC AAA CCT GCC ATG T
26841-CP2	TTC CTC AGC AGA GGG TGA A

Table III

Primers for IPAAA26841 subcloning and sequencing

Primer	Sequence (5'-3')
GCP Forward	G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GCC ACC</u>
GCP Reverse	GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA <i>ATG GTG ATG GTG ATG GTG</i>
26841-long-EX1	GCA GGC TTC <u>GCC ACC</u> ATG TCC CTG GGG CTA CTG AAA TTC C
26841-short-EX1	GCA GGC TTC <u>GCC ACC</u> ATG GAC TCC GCC CTT GAG TGG CT
26841-EX2	<i>GTG ATG GTG ATG GTG</i> GCA GAG GGT GAA GCG CCG GGC GC TGA
26841-SP1	TTT TCC CTG GTT TTT CTG GCA TCT CCC CTC GTG GCC ATA GAC TCC GCC CTT GAG TGG CT
SP2	ATG TGT CAC CAG CAG TTG GTC ATC TCT TGG TTT TCC CTG GTT TTT CTG GCA TCT CCC CTC GTG GCC ATA
SP3	G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC <u>GCC ACC</u> ATG TGT CAC CAG CAG TTG
pEAK12-F	GCC AGC TTG GCA CTT GAT GT
pEAK12-R	GAT GGA GGT GGA CGT GTC AG
SP6	ATT TAG GTG ACA CTA TAG
T7	TAA TAC GAC TCA CTA TAG GG

5 Underlined sequence = Kozak sequence

Bold = Stop codon

Italic sequence = His tag

~~A~~ = nucleotide mutated in IPAAA26841 sequence from G-A (Met-Ile)

4. Expression of IPAAA26841-Long-6HIS-V1 in mammalian cells (plasmid No. 12148)

4.1 Cell culture

5 Human Embryonic Kidney 293 cells expressing the Epstein-Barr virus Nuclear Antigen (HEK293-EBNA, Invitrogen) were maintained in suspension in Ex-cell VPRO serum-free medium (seed stock, maintenance medium, JRH). Sixteen to 20 hours prior to transfection (Day-1), cells were seeded in 2x T225 flasks (50 ml per flask in DMEM / F12 (1:1) containing 2% FBS seeding medium (JRH) at a density of 2×10^5 cells/ ml). The
10 next day (transfection day0) the transfection took place by using the JetPEITM reagent (2 μ l/ μ g of plasmid DNA, PolyPlus-transfection). For each flask, 113 μ g of plasmid No. 12148 was co-transfected with 2.3 μ g of GFP (fluorescent reporter gene). The transfection mix was then added to the 2xT225 flasks and incubated at 37⁰C (5%CO₂) for 6 days. Confirmation of positive transfection was done by qualitative fluorescence
15 examination at day 1 and day 6 (Axiovert 10 Zeiss).

On day 6 (harvest day), supernatants (100ml) from the two flasks were pooled and centrifuged (4°C, 400g) and placed into a pot bearing a unique identifier.

One aliquot (500 μ l) was kept for QC of the 6His-tagged protein (internal bioprocessing QC).

20 4.2 Purification process

The 100 ml culture medium sample containing the recombinant protein with a C-terminal 6His tag was diluted to a final volume of 200 ml with cold buffer A (50 mM NaH₂PO₄; 600 mM NaCl; 8.7 % (w/v) glycerol, pH 7.5). The sample was filtered through a 0.22 μ m sterile filter (Millipore, 500 ml filter unit) and kept at 4°C in a 250 ml sterile square
25 media bottle (Nalgene).

The purification was performed at 4°C on the VISION workstation (Applied Biosystems) connected to an automatic sample loader (Labomatic). The purification procedure was composed of two sequential steps, metal affinity chromatography on a Poros 20 MC

(Applied Biosystems) column charged with Ni ions (4.6 x 50 mm, 0.83 ml), followed by gel filtration on a Sephadex G-25 medium (Amersham Pharmacia) column (1,0 x 10 cm).

For the first chromatography step the metal affinity column was regenerated with 30 column volumes of EDTA solution (100 mM EDTA; 1 M NaCl; pH 8.0), recharged with
5 Ni ions through washing with 15 column volumes of a 100 mM NiSO₄ solution, washed with 10 column volumes of buffer A, followed by 7 column volumes of buffer B (50 mM NaH₂PO₄; 600 mM NaCl; 8.7 % (w/v) glycerol, 400 mM; imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15 mM imidazole. The sample was transferred, by the Labomatic sample loader, into a 200 ml sample loop and
10 subsequently charged onto the Ni metal affinity column at a flow rate of 10 ml/min. The column was washed with 12 column volumes of buffer A, followed by 28 column volumes of buffer A containing 20 mM imidazole. During the 20 mM imidazole wash loosely attached contaminating proteins were elution of the column. The recombinant His-tagged protein was finally eluted with 10 column volumes of buffer B at a flow rate
15 of 2 ml/min, and the eluted protein was collected in a 1.6 ml fraction.

For the second chromatography step, the Sephadex G-25 gel-filtration column was regenerated with 2 ml of buffer D (1.137 M NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM Na₂HPO₄; pH 7.2), and subsequently equilibrated with 4 column volumes of buffer C
20 (137 mM NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM Na₂HPO₄; 20 % (w/v) glycerol; pH 7.4). The peak fraction eluted from the Ni-column was automatically through the integrated sample loader on the VISION loaded onto the Sephadex G-25 column and the protein was eluted with buffer C at a flow rate of 2 ml/min. The desalted sample was recovered in a 2.2 ml fraction. The fraction was filtered through a 0.22 µm sterile centrifugation filter (Millipore), frozen and stored at -80°C. An aliquot of the sample was
25 analyzed on SDS-PAGE (4-12% NuPAGE gel; Novex) Western blot with anti-His antibodies.

Following the electrophoresis the proteins were electrotransferred from the gel to a nitrocellulose membrane at 290 mA for 1 hour at 4°C. The membrane was blocked with 5 % milk powder in buffer E (137 mM NaCl; 2.7 mM KCl; 1.5 mM KH₂PO₄; 8 mM
30 Na₂HPO₄; 0.1 % Tween 20, pH 7.4) for 1 h at room temperature, and subsequently

incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G-18 and H-15, 0.2ug/ml each; Santa Cruz) in 2.5 % milk powder in buffer E overnight at 4°C. After further 1 hour incubation at room temperature, the membrane was washed with buffer E (3 x 10 min), and then incubated with a secondary HRP-conjugated anti-rabbit antibody
5 (DAKO, HRP 0399) diluted 1/3000 in buffer E containing 2.5 % milk powder for 2 hours at room temperature. After washing with buffer E (3 x 10 minutes), the membrane was developed with the ECL kit (Amersham Pharmacia) for 1 min. The membrane was subsequently exposed to a Hyperfilm (Amersham Pharmacia), the film developed and the western blot image visually analyzed.

Sequence Listing

SEQ ID NO: 1 (INSP035 cloned nucleotide sequence)

1 ATGTCCCTGG GGCTACTGAA ATTCCAGGCA GTGGGTGAAG AGGACGAGGA
 51 GGATGAGGAG GGGGAGAGCC TGGACTCTGT GAAGGCACTG ACAGCCAAGC
 5 101 TGCAGCTGCA GACTCGGCGG CCCTCATATC TGGAGTGGAC AGCCCAGGTC
 151 CAGAGCCAGG CCTGGCGCAG GGCCCAAGCC AAACCTGGAC CAGGGGGACC
 201 TGGGGACATC TGTGGTTTCG ACTCAATGGA CTCCGCCCTT GAGTGGCTCC
 251 GACGGGAGCT GCGGGAGATG CAGGCGCAGG ACAGGCAGCT GGCAGGGCAG
 301 CTGCTGCGGC TCGGGGCCCA GCTGCACCGA CTGAAGATGG ACCAAGCCTG
 10 351 TCACCTGCAC CAGGAGCTGC TGGATGAGGC CGAGCTGGAG CTGGAGCTGG
 401 AGCCCGGGGC CGGCCTAGCC CTGGCCCCGC TGCTGCGGCA CCTGGGCCTC
 451 ACGCGCATGA ACATCAGCGC CCGGCGCTTC ACCCTCTGCT GA

SEQ ID NO:2 (INSP035 cloned protein sequence)

15 1 MSLGLLKFQA VGEDEEDEE GESLDSVKAL TAKLQLQTRR PSYLEWTAQV
 51 QSQAWRRAQA KPGPGGPGDI CGFDSMDSAL EWLRLRELREM QAQDRQLAGQ
 101 LLRLRAQLHR LKMDQACHLH QELLDEAELE LELEPGAGLA LAPLLRHLGL
 151 TRMNISARRF TLC

20 SEQ ID NO:17 (predicted Nucleotide sequence exon 1 of INSP035)

1 ATGGACTCCG CCCTTGAGTG GCTCCGACGG GAGCTG

SEQ ID NO:18 (predicted protein sequence exon 1 of INSP035)

1 MDSALEWLRR EL

25

SEQ ID NO:19 (predicted nucleotide sequence exon 2 of INSP035)

1 CGGGAGATGC AGGCGCAGGA CAGGCAGCTG GCAGGGCAGC TGCTGCGGCT
 51 GCGGGCCCAG CTGCACCGAC TGAAGATGGA CCAAGCCTGT CACCTGCACC
 101 AGGAGCTGCT GGATGAGGCC GAGCTGGAGC TGGAGCTGGA GCCCGGGGCC
 30 151 GGCCTAGCCC TGGCCCCGCT GCTGCGGCAC CTGGGCCTCA CGCGCATGAA
 201 CATCAGCGCC CGGCGCTTCA CCCTCTGCTG A

SEQ ID NO:20 (predicted protein sequence exon 2 of INSP035)

1 REMQAQDRQL AGQLRLRAQ LHRLKMDQAC HLHQELLDEA ELELELEPGA
 35 51 GLALAPLLRH LGLTRMNISA RRFTLC

SEQ ID NO:21 (predicted nucleotide sequence of INSP035/INSP035 nucleotide sequence from 2nd Methionine onwards)

1 ATGGACTCCG CCCTTGAGTG GCTCCGACGG GAGCTGCGGG AGATGCAGGC
 51 GCAGGACAGG CAGCTGGCAG GGCAGCTGCT GCGGCTGCGG GCCCAGCTGC
 5 101 ACCGACTGAA GATGGACCAA GCCTGTCACC TGCACCAGGA GCTGCTGGAT
 151 GAGGCCGAGC TGGAGCTGGA GCTGGAGCCC GGGGCCGGCC TAGCCCTGGC
 201 CCCGCTGCTG CGGCACCTGG GCCTCACGCG CATGAACATC AGCGCCCGGC
 251 GCTTCACCCT CTGCTGA

10 SEQ ID NO:22 (predicted protein sequence of INSP035/ INSP035 protein sequence from 2nd Methionine onwards)

1 MDSALEWLRR ELREMQAQDR QLAGQLRLR AQLHRLKMDQ ACHLHQELLD
 51 EAELELELEP GAGLALAPLL RHLGLTRMNI SARRETLC

15 SEQ ID NO:23 (INSP035 nucleotide sequence from 3rd Methionine onwards)

1 ATGCAGGCGC AGGACAGGCA GCTGGCAGGG CAGCTGCTGC GGCTGCGGGC
 51 CCAGCTGCAC CGACTGAAGA TGGACCAAGC CTGTCACCTG CACCAGGAGC
 101 TGCTGGATGA GGCCGAGCTG GAGCTGGAGC TGGAGCCCGG GGCCGGCCTA
 151 GCCCTGGCCC CGCTGCTGCG GCACCTGGGC CTCACGCGCA TGAACATCAG
 20 201 CGCCCGGCGC TTCACCCTCT GCTGA

SEQ ID NO:24 (INSP035 protein sequence from 3rd Methionine onwards)

1 MQAQDRQLAG QLLRLRAQLH RLKMDQACHL HQELLDEAEL ELELEPGAGL
 51 ALAPLLRHLG LTRMNISARR FTLC

25

Additional diseases include bulimia nervosa (see Monteleone, P., et al., Psychosom Med 2002 Nov-Dec; 64(6):874-9, end-stage renal disease (Pecoits-Filho, R. et al., Eur J. Clin Invest 2002 Nov:32(11):811-7, breast, prostate, endometrium, colon and gall bladder cancers resulting from obesity (J Nutr 2002 Nov: 132 (11 Suppl):2451S-2455S), angiogenesis, wound healing, lipolysis, blood pressure homeostasis, and diseases associated with satiety control (Fruhbeck G. Nutr Rev 2002 Oct: 60(10 Pt 2):S47-55; discussion S68-84, 85-87) and cardiovascular disease related to obesity (Circulation 2002 Oct 8; 106(15):1919-24)

CLAIMS

1. A polypeptide, which polypeptide:
 - (i) comprises or consists of the amino acid sequence as recited in SEQ ID NO:2;
 - 5 (ii) is a fragment thereof having secreted protein function, particularly four helical bundle cytokine function, more particularly having long chain cytokines function and even more particularly, having leptin function, or having an antigenic determinant in common with the polypeptides of (i); or
 - 10 (iii) is a functional equivalent of (i) or (ii).
2. A polypeptide according to claim 1 which functions as a secreted protein, in particular, is a member of the four helical bundle cytokine family, more particularly, is a member of the long chain cytokines family and most particularly, is a leptin.
3. A polypeptide which is a functional equivalent according to claim 1(iii), is
15 homologous to the amino acid sequence as recited in SEQ ID NO: 2, and has secreted protein activity, in particular, four helical bundle cytokine activity, more particularly long chain cytokine activity, even more particularly, leptin activity.
4. A fragment or functional equivalent according to any one of the preceding claims, which has greater than 80% sequence identity with the amino acid sequence recited
20 in SEQ ID NO:2 or with active fragments thereof, preferably greater than 90%, 95%, 98% or 99% sequence identity.
5. A functional equivalent according to any one of the preceding claims, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in SEQ ID NO:2.
- 25 6. A fragment as recited in any one of claims 1-2 or 4 having an antigenic determinant in common with a polypeptide of part (i) of claim 1, which consists of 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more) amino acid residues from the sequence of SEQ ID NO:2.

7. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding claims.
8. A purified nucleic acid molecule according to claim 7, which has the nucleic acid sequence as recited in SEQ ID NO:1 or is a redundant equivalent or fragment thereof.
9. A purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule according to claim 7 or claim 8.
10. A vector comprising a nucleic acid molecule as recited in any one of claims 7-9.
11. A host cell transformed with a vector according to claim 10.
12. A ligand which binds specifically to, and which preferably inhibits the secreted protein activity, particularly, the four helical bundle cytokine activity, more particularly, the long chain cytokine activity and even more particularly, the leptin activity of a polypeptide according to any one of claims 1-6.
13. A ligand according to claim 12, which is an antibody.
14. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1-6.
15. A compound according to claim 14 that binds to a polypeptide according to any one of claims 1-6 without inducing any of the biological effects of the polypeptide.
16. A compound according to claim 14 or claim 15, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
17. A polypeptide according to any one of claim 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or claim 13, or a compound according to any one of claims 14-16, for use in therapy or diagnosis of disease.
18. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of claim 1-6, or assessing the activity of a polypeptide according to any one of claims 1-6, in tissue from said patient and comparing said level of expression or activity to a

control level, wherein a level that is different to said control level is indicative of disease.

19. A method according to claim 18 that is carried out *in vitro*.

20. A method according to claim 18 or claim 19, which comprises the steps of: (a)
5 contacting a ligand according to claim 12 or claim 13 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

21. A method according to claim 18 or claim 19, comprising the steps of:

- 10 a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the probe;
- b) contacting a control sample with said probe under the same conditions used in step a); and
- 15 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

22. A method according to claim 18 or claim 19, comprising:

- 20 a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the primer;
- b) contacting a control sample with said primer under the same conditions used in step a); and
- c) amplifying the sampled nucleic acid; and
- 25 d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

23. A method according to claim 18 or claim 19 comprising:

a) obtaining a tissue sample from a patient being tested for disease;

b) isolating a nucleic acid molecule according to any one of claims 7-9 from said tissue sample; and

5 c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

10 24. The method of claim 23, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.

15 25. The method of either claim 23 or 24, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

20 26. A method according to any one of claims 18-25, wherein said disease is selected from cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorders, infections and other pathological conditions, particularly immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, 25 rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease; airway

inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, even more particularly human herpesvirus 5 (cytomegalovirus) infection..

27. Use of a polypeptide according to any one of claims 1-6 as a secreted protein, in particular as a polypeptide member of the four helical bundle cytokine superfamily, more particularly, as a member of the long chain cytokines family, most particularly, as a leptin.

28. A pharmaceutical composition comprising a polypeptide according to any one of claim 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or 13, or a compound according to any one of claims 14-16.

29. A vaccine composition comprising a polypeptide according to any one of claims 1-6 or a nucleic acid molecule according to any one of claims 7-9.

30. A polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or 13, a compound according to any one of claims 14-16, or a pharmaceutical composition according to claim 28, for use in the manufacture of a medicament for the treatment of cell proliferative disorders, autoimmune/inflammatory disorders, cardiovascular disorders, neurological disorders, developmental disorders, metabolic disorders, infections and other pathological conditions, particularly, immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic

shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection, even more particularly human herpesvirus 5 (cytomegalovirus) infection.

31. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claim 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or 13, or a compound according to any one of claims 14-16, or a pharmaceutical composition according to claim 28.

32. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.

33. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.

34. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1-6, or the level of expression of a nucleic acid molecule according to any one of claims 7-9 in tissue from said patient, wherein

altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.

35. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1-6, or a nucleic acid molecule according to any one of claims 7-9 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
36. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 7-9; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
37. The kit of claim 36, further comprising a third container holding an agent for digesting unhybridised RNA.
38. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 7-9.
39. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1-6; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
40. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1-6.
41. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 40 with a candidate compound and determining the effect of the compound on the disease of the animal.

1/30

Figure 1

Genome Threader results – Energy Scores

Rank	PDB Code	Norm. Align. Score	Raw Align. Score	%ID	%Struct. Aligned	%Query Seq. Aligned	Pairwise Energy	Solvation Energy	Neural Net Score	Confidence	From Pos. for Query	To Pos. for Query	From Pos. for Target	To Pos. for Target	Alignment Length	Local=0 Global=1
1	1ax8-100 (biopendium)	0.01	56	32.3	46.9	63.6	-76.58	-1.78	0.941	79	1	57	38	99	62	0
2	1g2a-100 (biopendium)	0.78	60	17.7	27.1	97.7	-61.58	0.54	0.935	78	1	87	154	248	56	0
3	1gdr-100 (biopendium)	0.54	56	14.9	37.7	81.8	-81.14	0.95	0.928	74	1	73	110	179	74	0
4	1b1b-100 (biopendium)	0.69	55	24.1	37.9	59.1	-40.40	2.78	0.924	73	20	72	69	122	54	0
5	1g5a-100 (biopendium)	0.09	56	5.6	16.1	55.7	-0.84	-0.98	0.915	69	8	57	271	323	54	0
6	1f1y-100 (biopendium)	0.80	56	21.2	9.4	81.8	-63.33	-4.21	0.888	61	5	77	353	435	85	0

<Previous 1 Next>

2/30

Figure 2

Alignment

```
Alignment Types: Local
Sequence A Ranges: 1 -> 130
Sequence B Ranges: 1 -> 88
Gap Open Penalty: -11
Gap Extend Penalty: -1
Scoring Matrix: /usr/local/BLOSUM62
Profile As: ../gaps_files/profiles/lax8-100.pro
Sequence B: /tmp/gcr_117/34.fa
DB Alignments: -
GT Alignments: -
View Alignments: Yes
Reverse GT Alignments: No
Score Length Num ID No. type Overlap tID C+ve From To From To
SCORES: 56 62 20 25 93 32.3 40 3 38 99 1 57
Length1 Length2 Normalised Score
SCORE2: 130 88 33.009717
10| 20| 30| 40| 50| 60| 70|
lax8-100 Lqkvqddkrlqlavtrindildflpqlhpilqlgrmdotlavycolltsmesrnnvqiisndlenlrldl
User-Seq -----MDSALEWLRRELRERMOQOD-RQLAQQLRLRAQ
10| 20| 30|
60| 90| 100| 110| 120| 130|
lax8-100 LHVLAFLSKSCHLEERASGLETLDSLGGVLEsgyvetvvalerlqgslodmlwqldlepgc
User-Seq LHRLEKMDQACHLHC---EBLDEAELELEtepgaglelapilrhlgltcrmlsarrtlc
40| 50| 60| 70| 80|
```


3/30

Figure 3


predicted nucleotide sequence of INSP035 (IPAAA26841) with translation

```

1  CACACACCCA TCTGCTCACT CACCCTGGCA CATTGAGCCC CCCTAACCCA CCTTGAACAT
61  TGACCACCAC AACTCCCTG GCACGCTCTT CTCACCCTCA ACTTCTGCCA CCTCTCCCTG
121  GGCAATACTG CCAGCCTTTC CCTAATCTCA GAGCTGCAGC CCTGCCCTGT CACTCACCTC
181  AAACCTGCCA TGTCCCTGGG GCTACTGAAA TTCCAGGCAG TGGGTGAAGA GGACGAGGAG
    26841-CP1      m s l g l l k f q a v g e e d e e
241  GATGAGGAGG GGGAGAGCCT GGACTCTGTG AAGGCACTGA CAGCCAAGCT GCAGCTGCAG
    d e e g e s l d s v k a l t a k l q l q
301  ACTCGGCGGC CCTCATATCT GGAGTGGACA GCCCAGGTCC AGAGCCAGGC CTGGCGCAGG
    t r r p s y l e w t a q v q s q a w r r
361  GCCCAAGCCA AACCTGGACC AGGGGGACCT GGGGACATCT GTGGTTTCGA CTCAATGGAC
    a q a k p g p g g p g d i c g f d s m d
421  TCCGCCCTTG AGTGGCTCCG ACGGGAGCTG CGGGAGATGC AGGCGCAGGA CAGGCAGCTG
    s a l e w l r r e l r e m q a q d r q l
481  GCAGGGCAGC TGCTGCGGCT GCGGGCCCAG CTGCACCGAC TGAAGATGGA CCAAGCCTGT
    a g q l l r l r a q l h r l k m d q a c
541  CACCTGCACC AGGAGCTGCT GGATGAGGCC GAGCTGGAGC TGGAGCTGGA GCCCGGGGCC
    h l h q e l l d e a e l e l e l e p g a
601  GGCCTAGCCC TGGCCCCGCT GCTGCGGCAC CTGGGCCTCA CGCGCATGAA CATCAGCGCC
    g l a l a p l l r h l g l t r m n i s a
661  CGGCGCTTCA CCCTCTGCTG AGGAACACCT GTGCCCCCGG ACTCCCCGCC CCCTCTCCCA
    r r f t l c -
    26841-CP2
721  ATGCCGCTTC CCCTGCCTGC CTGGGAAGAG GAAAGGGAGG GGTGCCCCAG AGGCACCAGC
781  TCCTGGCGGG GGAGGAGGAA CATTGAGGTT TCTGAGAGCT GAATTCCAAG AGTGCAAAAC
841  CCCAGCATCC TGTTTCCTCT GCTGACCCAG CTGGGAGGGG GAGGAGGAGG AGCTCACACC
901  CTCAAACCTC TCAATAAACG CTTTCTCTGG TTCCC

```

Position and sense of PCR primers



4/30

Figure 4

Nucleotide sequence with translation of PCR product cloned using primers 26841-CP1 and 26841-CP2.

```

1  CACCTCAAAC CTGCCATGTC CCTGGGGCTA CTGAAATTCC AGGCAGTGGG TGAAGAGGAC
      m s l g l l k f q a v g e e d

61  GAGGAGGATG AGGAGGGGGA GAGCCTGGAC TCTGTGAAGG CACTGACAGC CAAGCTGCAG
      e e d e e g e s l d s v k a l t a k l q

121 CTGCAGACTC GCGGGCCCTC ATATCTGGAG TGGACAGCCC AGGTCCAGAG CCAGGCCTGG
      l q t r r p s y l e w t a q v q s q a w

181 CGCAGGGCCC AAGCCAAACC TGGACCAGGG GGACCTGGGG ACATCTGTGG TTTCGACTCA
      r r a q a k p g p g g p g d i c g f d s

241 ATGGACTCCG CCCTTGAGTG GCTCCGACGG GAGCTGCGGG AGATGCAGGC GCAGGACAGG
      m d s a l e w l r r e l r e m q a q d r

301 CAGCTGGCAG GGCAGCTGCT GCGGCTGCGG GCCCAGCTGC ACCGACTGAA GATGGACCAA
      q l a g q l l r l r a q l h r l k m d q

361 GCCTGTCACC TGCACCAGGA GCTGCTGGAT GAGGCCGAGC TGGAGCTGGA GCTGGAGCCC
      a c h l h q e l l d e a e l e l e l e p


421 GGGGCCGGCC TAGCCCTGGC CCCGCTGCTG CGGCACCTGG GCCTCACGCG CATGAACATC
      g a g l a l a p l l r h l g l t r m n i

481 AGCGCCCGGC GCTTCACCCT CTGCTGAGGA A
      s a r r f t l c

```


Molecule Features:

Type	Start	End	Name	Description
REGION	2	216		lac promoter region
REGION	205	221		M13 reverse priming site
REGION	217	294		LacZa-ccdB gene fusion'
MARKER	243		T3	
REGION	262	294		Polylinker'
REGION	294	294		TOPO cloning site'
MARKER	523		C	Putative ATG start codon
MARKER	565		C	Putative ATG start codon
MARKER	790		C	Putative ATG start codon
GENE	790	294	C IPAAA26841	cds
REGION	805	295	C	Inserted PCR product 26842_19_2
REGION	806	1321		'LacZa-ccdB gene fusion
REGION	806	823		'Polylinker
REGION	806	806		'TOPO cloning site
MARKER	858		C T7	
REGION	881	866	C	-20M13 forward priming site
GENE	1670	2464	KanR	
REGION	2656	2660		Ribosome binding site
GENE	2668	3528	AmpR	
REGION	3673	4346	pUC ori	



6/30

Figure 6

Map of expression vector pEAK12d


Molecule: pEAK12 d, 8760 bps DNA Circular

File Name: pEAK12DEST.cm5

Description: Mammalian cell expression vector (plasmid ID 11345)

Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	Amp	
REGION	1690	2795	EF-1alpha	
REGION	2703	2722		position of pEAK12F primer
REGION	2796	2845		MCS
MARKER	2855		attR1	
GENE	3256	3915	CmR	
GENE	4257	4562	ccdB	
MARKER	4603		C attR2	
REGION	4733	4733		MCS
REGION	4734	5162		poly A/splice
REGION	4819	4848	C	position of pEAK12R primer
GENE	5781	5163	C PUR	PUROMYCIN
REGION	6005	5782	C tK	tK promoter
REGION	6500	6006	C Ori P	
GENE	8552	6500	C EBNA-1	
REGION	8553	8752	sv40	



7/30

Figure 7


Map of Gateway vector pDONR201

Molecule: pDONR201, 4470 bps DNA Circular
 File Name: pDONR201.cm5

Description: Gateway entry vector (Invitrogen)- plasmid ID# 13309

Molecule Features:

Type	Start	End	Name
REGION	332	563	attP1
GENE	959	1264	ccdB
REGION	2513	2744	attP2
GENE	2868	3677	KanR
REGION	3794	4467	pUC ori



8/30

Figure 8


Map of pEAK12d-IPAAA26841-long-6HIS

Molecule: pEAK12d-IPAAA26841-long-6HIS, 7456 bps DNA Circular

File Name: 12148[1].cm5

Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	AmpR	
REGION	1690	2795	EF-1a	
REGION	2702	2722		pEAK12F
MARKER	2855		attB1	
GENE	2888	3394	26841-long-6HIS	
MARKER	3410		attB2	
REGION	3430	3858		poly A/splice
REGION	3544	3525	C	pEAK12R
GENE	4477	3859	C	PurR
REGION	4701	4478	C	tK promoter
REGION	5196	4702	C Ori P	
GENE	7248	5196	C EBNA-1	
REGION	7249	7448	sv40	



9/30


Figure 9

Map of plasmid pEAK12d-IPAAA26841-short-6HIS

Molecule: pEAK12d-IPAAA26841-short-6HIS, 7231 bps DNA Circular
 File Name: 12686[1].cm5

Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	AmpR	
REGION	1690	2795	EF-1a	
REGION	2703	2722		pEAK12F
MARKER	2855		attB1	
GENE	2888	3169	IPAAA26841-short-6HIS	
MARKER	3185		attB2	
REGION	3205	3633		poly A/splice
REGION	3319	3300	C	pEAK12R
GENE	4252	3634	C	PurR
REGION	4476	4253	C	tK promoter
REGION	4971	4477	C Ori P	
GENE	7023	4971	C EBNA-1	
REGION	7024	7223	sv40	



10/30


Figure 10

Map of plasmid pEAK12s-sigptd-IPAAA26841-short

Molecule: pEAK12d-sigptd-IPAAA26841-6HIS-V1, 7297 bps DNA
 Circular
 File Name: 12737[1].cm5

Molecule Features:

Type	Start	End	Name	Description
REGION	2	595		pmb-ori
GENE	596	1519	AmpR	
REGION	1690	2795	EF-1a	
REGION	2703	2722		pEAK12F
MARKER	2855		attB1	
GENE	2888	3235	sigptd-IPAAA26841-6HIS	
MARKER	3251		attB2	
REGION	3271	3699		poly A/splice
REGION	3385	3366 C		pEAK12R
GENE	4318	3700 C		PurR
REGION	4542	4319 C		tK promoter
REGION	5037	4543 C	Ori P	
GENE	7089	5037 C	EBNA-1	
REGION	7090	7289	sv40	



11/30

Figure 11

PCR4 TOPO IPAAA26841

```
1  AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC
61  ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC
121 TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA
181 TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA
241 GAATTAACCC TACTAAAGG GACTAGTCCT GCAGGTTTAA ACGAATTCGC CCTTTTCCTC
301 AGCAGAGGGT GAAGCGCCGG GCGCTGATGT TCATGCGCGT GAGGCCCAGG TGCCGCAGCA
361 GCGGGGCCAG GGCTAGGCCG GCCCCGGGCT CCAGCTCCAG CTCCAGCTCG GCCTCATCCA
421 GCAGCTCCTG GTGCAGGTGA CAGGCTTGGT CCATCTTCAG TCGGTGCAGC TGGGCCCGCA
481 GCCGCAGCAG CTGCCCTGCC AGCTGCCTGT CCTGCGCCTG CATCTCCCGC AGCTCCCGTC
541 GGAGCCACTC AAGGGCGGAG TCCATTGAGT CGAAACCACA GATGTCCCCA GGTCCCCCTG
601 GTCCAGGTTT GGCTTGGGCC CTGCGCCAGG CCTGGCTCTG GACCTGGGCT GTCCACTCCA
661 GATATGAGGG CCGCCGAGTC TGCAGCTGCA GCTTGGCTGT CAGTGCCTTC ACAGAGTCCA
721 GGCTCTCCCC CTCCTCATCC TCCTCGTCCT CTTACCCAC TGCCTGGAAT TTCAGTAGCC
781 CCAGGGACAT GGCAGGTTTG AGGTGAAGGG CGAATTCGCG GCCGCTAAAT TCAATTCGCC
841 CTATAGTGAG TCGTATTACA ATTCACTGGC CGTCGTTTTA CAACGTCGTG ACTGGGAAAA
901 CCCTGGCGTT ACCCAACTTA ATCGCCTTGC AGCACATCCC CCTTTCGCCA GCTGGCGTAA
961 TAGCGAAGAG GCCCGCACCG ATCGCCCTTC CCAACAGTTG CGCAGCCTAT ACGTACGGCA
1021 GTTTAAGGTT TACACCTATA AAAGAGAGAG CCGTTATCGT CTGTTTGTGG ATGTACAGAG
1081 TGATATTATT GACACGCCGG GGCGACGGAT GGTGATCCCC CTGGCCAGTG CACGTCTGCT
1141 GTCAGATAAA GTCTCCCGTG AACTTTACCC GGTGGTGCAT ATCGGGGATG AAAGCTGGCG
1201 CATGATGACC ACCGATATGG CCAGTGTGCC GGTCTCCGTT ATCGGGGAAG AAGTGGCTGA
1261 TCTCAGCCAC CGCGAAAATG ACATCAAAAA CGCCATTAAC CTGATGTTCT GGGGAATATA
1321 AATGTCAGGC ATGAGATTAT CAAAAGGAT CTTCACCTAG ATCCTTTTCA CGTAGAAAGC
1381 CAGTCCGCAG AAACGGTGCT GACCCCGGAT GAATGTCAGC TACTGGGCTA TCTGGACAAG
1441 GGAAAACGCA AGCGCAAAGA GAAAGCAGGT AGCTTGCACT GGGCTTACAT GGCGATAGCT
1501 AGACTGGGCG GTTTTATGGA CAGCAAGCGA ACCGGAATTG CCAGCTGGGG CGCCCTCTGG
1561 TAAGGTTGGG AAGCCCTGCA AAGTAAACTG GATGGCTTTC TCGCCGCCAA GGATCTGATG
1621 GCGCAGGGGA TCAAGCTCTG ATCAAGAGAC AGGATGAGGA TCGTTTCGCA TGATTGAACA
1681 AGATGGATTG CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG
1741 GGCACAACAG ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG
1801 CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC AAGACGAGGC
1861 AGCGCGGCTA TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC TCGACGTTGT
1921 CACTGAAGCG GGAAGGGACT GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC
```


12/30

1981 ATCTCACCTT GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA
2041 TACGCTTGAT CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC
2101 ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG
2161 GCTCGCGCCA GCCGAACTGT TCGCCAGGCT CAAGGCGAGC ATGCCCCGACG GCGAGGATCT
2221 CGTCGTGACC CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG GCCGCTTTTC
2281 TGGATTCATC GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC
2341 TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA
2401 CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT
2461 CTGAATTATT AACGCTTACA ATTTCTGAT GCGGTATTTT CTCCTTACGC ATCTGTGCGG
2521 TATTTACAC CGCATACAGG TGGCACTTTT CGGGGAAATG TGCGCGGAAC CCCTATTTGT
2581 TTATTTTTCT AAATACATTC AAATATGTAT CCGCTCATGA GACAATAACC CTGATAAATG
2641 CTTCAATAAT ATTGAAAAG GAAGAGTATG AGTATTCAAC ATTTCCGTGT CGCCCTTATT
2701 CCCTTTTTTG CGGCATTTTG CCTTCCTGTT TTTGCTCACC CAGAAACGCT GGTGAAAGTA
2761 AAAGATGCTG AAGATCAGTT GGGTGCACGA GTGGGTTACA TCGAACTGGA TCTCAACAGC
2821 GGTAAGATCC TTGAGAGTTT TCGCCCCGAA GAACGTTTTT CAATGATGAG CACTTTTAAA
2881 GTTCTGCTAT GTGGCGCGGT ATTATCCCGT ATTGACGCCG GGCAAGAGCA ACTCGGTCGC
2941 CGCATACACT ATTCTCAGAA TGA CTGTTGTT GAGTACTCAC CAGTCACAGA AAAGCATCTT
3001 ACGGATGGCA TGACAGTAAG AGAATTATGC AGTGCTGCCA TAACCATGAG TGATAACACT
3061 GCGGCCAACT TACTTCTGAC AACGATCGGA GGACCGAAGG AGCTAACCGC TTTTTTGCAC
3121 AACATGGGGG ATCATGTAAC TCGCCTTGAT CGTTGGGAAC CGGAGCTGAA TGAAGCCATA
3181 CCAAACGACG AGCGTGACAC CACGATGCCT GTAGCAATGG CAACAACGTT GCGCAAACATA
3241 TTAAGTGGCG AACTACTTAC TCTAGCTTCC CGGCAACAAT TAATAGACTG GATGGAGGCG
3301 GATAAAGTTG CAGGACCACT TCTGCGCTCG GCCCTTCCGG CTGGCTGGTT TATTGCTGAT
3361 AAATCTGGAG CCGGTGAGCG TGGGTCTCGC GGTATCATTG CAGCACTGGG GCCAGATGGT
3421 AAGCCCTCCC GTATCGTAGT TATCTACACG ACGGGGAGTC AGGCAACTAT GGATGAACGA
3481 AATAGACAGA TCGCTGAGAT AGGTGCCTCA CTGATTAAGC ATTGGTAACT GTCAGACCAA
3541 GTTTACTCAT ATATACTTTA GATTGATTTA AAACCTCATT TTTAATTTAA AAGGATCTAG
3601 GTGAAGATCC TTTTGTGATA TCTCATGACC AAAATCCCTT AACGTGAGTT TTCGTTCCAC
3661 TGAGCGTCAG ACCCCGTAGA AAAGATCAAA GGATCTTCTT GAGATCCTTT TTTTCTGCGC
3721 GTAATCTGCT GCTTGCAAAC AAAAAACCA CCGCTACCAG CGGTGGTTTG TTTGCCGGAT
3781 CAAGAGCTAC CAACTCTTTT TCCGAAGGTA ACTGGCTTCA GCAGAGCGCA GATACCAAAT
3841 ACTGTCCTTC TAGTG TAGCC GTAGTTAGGC CACCACTTCA AGAACTCTGT AGCACCGCCT
3901 ACATACCTCG CTCTGCTAAT CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT
3961 CTTACCGGGT TGGACTCAAG ACGATAGTTA CCGGATAAGG CGCAGCGGTC GGGCTGAACG
4021 GGGGGTTCGT GCACACAGCC CAGCTTGGAG CGAACGACCT ACACCGAACT GAGATACCTA
4081 CAGCGTGAGC TATGAGAAAG CGCCACGCTT CCCGAAGGGA GAAAGGCGGA CAGGTATCCG

13/30

4141 GTAAGCGGCA GGGTCGGAAC AGGAGAGCGC ACGAGGGAGC TTCCAGGGGG AAACGCCTGG
4201 TATCTTTATA GTCCTGTCGG GTTTCGCCAC CTCTGACTTG AGCGTCGATT TTTGTGATGC
4261 TCGTCAGGGG GGCGGAGCCT ATGGAAAAAC GCCAGCAACG CGGCCTTTTT ACGGTCCTG
4321 GGCTTTTGCT GGCCCTTTGC TCACATGTTT TTCCTGCGT TATCCCCTGA TTCTGTGGAT
4381 AACCGTATTA CCGCCTTTGA GTGAGCTGAT ACCGCTCGCC GCAGCCGAAC GACCGAGCGC
4441 AGCGAGTCAG TGAGCGAGGA AGCGGAAG

14/30

Figure 12

pEAK12D-IPAAA26841long-6His

```
1  GCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG
61  GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACCTGGCT TCAGCAGAGC GCAGATACCA
121 AATACTGTCC TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG
181 CCTACATACC TCGCTCTGCT GAAGCCAGTT ACCAGTGGCT GCTGCCAGTG GCGATAAGTC
241 GTGTCTTACC GGGTTGGACT CAAGAGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA
301 ACGGGGGGTT CGTGACACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC
361 CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT
421 CCGGTAAGCG GCAGGGTTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
481 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTGTGA
541 TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCAAGCTA GAGTTTAAAC
601 TTGACAGATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAAAGTAT
661 GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT
721 TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCA GAAGATCACT TGGGTGCGCG
781 AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA
841 AGAACGTTTC CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG
901 TATTGATGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA ATGACTTGGT
961 TGAATACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG
1021 CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA CAACTATCGG
1081 AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA
1141 TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC
1201 TGTAACAATG GCAACAACGT TGCGAAAACT ATTAACCTGGC GAACTACTTA CTCTAGCTTC
1261 CCGGCAACAA CTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC
1321 GGCATTCCG GCTGGCTGGT TTATTGCTGA TAAATCAGGA GCCGGTGAGC GTGGGTCACG
1381 CGGTATCATT GCAGCACTGG GGCCGGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC
1441 TACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC
1501 ACTGATTAAG CATTGGTAAG GATAAATTTT TGGTAAGGAG GACACGTATG GAAGTGGGCA
1561 AGTTGGGGAA GCCGTATCCG TTGCTGAATC TGGCATATGT GGGAGTATAA GACGCGCAGC
1621 GTCGCATCAG GCATTTTTTT CTGCGCCAAT GCAAAAAGGC CATCCGTCAG GATGGCCTTT
1681 CGGCATAACT AGTGAGGCTC CGGTGCCCCG CAGTGGGCAG AGCGCACATC GCCCACAGTC
1741 CCCGAGAAGT TGGGGGGAGG GGTCGGCAAT TGAACCGGTG CCTAGAGAAG GTGGCGCGGG
1801 GTAAACTGGG AAAGTGATGT CGTGTAAGTG CTCCGCCTTT TTCCCGAGGG TGGGGGAGAA
1861 CCGTATATAA GTGCAGTAGT CGCCGTGAAC GTTCTTTTTT GCAACGGGTT TGCCGCCAGA
1921 ACACAGGTAA GTGCCGTGTG TGGTTCCCGC GGGCCTGGCC TCTTTACGGG TTATGGCCCT
```


15/30

1981 TCGGTGCCTT GAATTACTTC CACCTGGCTG CAGTACGTGA TTCTTGATCC CGAGCTTCGG
2041 GTTGGAAGTG GGTGGGAGAG TTCGAGGCCT TGCCTTAAG GAGCCCCTTC GCCTCGTGCT
2101 TGAGTTGAGG CCTGGCCTGG GCGCTGGGGC CGCCGCGTGC GAATCTGGTG GCACCTTCGC
2161 GCCTGTCTCG CTGCTTTCGA TAAGTCTCTA GCCATTTAAA ATTTTGTGATG ACCTGCTGCG
2221 ACGCTTTTTT TCTGGCAAGA TAGTCTTGTA AATGCGGGCC AAGACGATCT GCACACTGGT
2281 ATTTTCGGTTT TTGGGGCCGC GGGCGGCGAC GGGGCCCGTG CGTCCCAGCG CACATGCATG
2341 TTCGGCGAGG CGGGGCCTGC GAGCGCGGCC ACCGAGAATC GGACGGGGGT AGTCTCAAGC
2401 TGGCCGGCCT GCTCTGGTGC CTGGCCTCGC GCCGCCGTGT ATCGCCCCGC CCTGGGCGGC
2461 AAGGCTGGGA GCTCAAAATG GAGGACGCGG CGCTCGGGAG AGCGGGCGGG TGAGTCACCC
2521 ACACAAAGGA AAAGGGCCTT TCCGTCCTCA GCCGTCGCTT CATGTGACTC CACGGAGTAC
2581 CGGGCGCCGT CCAGGCACCT CGATTAGTTC TCGAGCTTTT GGAGTACGTC GTCTTTAGGT
2641 TGGGGGGAGG GGTTTTATGC GATGGAGTTT CCCACACTG AGTGGGTGGA GACTGAAGTT
2701 AGGCCAGCTT GGCACCTGAT GTAATTCTCC TTGGAATTTG CCCTTTTTGA GTTTGGATCT
2761 TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAATTAATA CGACTACTA TAGGGAGACT
2821 TCTTTCTCCC ATTTTCAGGTG TCGTAAGCTA TCAAACAAGT TTGTACAAAA AAGCAGGCTT
2881 CGCCACCATG TCCCTGGGGC TACTGAAATT CCAGGCAGTG GGTGAAGAGG ACGAGGAGGA
2941 TGAGGAGGGG GAGAGCCTGG ACTCTGTGAA GGCACCTGACA GCCAAGCTGC AGCTGCAGAC
3001 TCGGCGGGCC TCATATCTGG AGTGGACAGC CCAGGTCCAG AGCCAGGCCT GGCGCAGGGC
3061 CCAAGCCAAA CCTGGACCAG GGGGACCTGG GGACATCTGT GGTTCGACT CAATGGACTC
3121 CGCCCTTGAG TGGCTCCGAC GGGAGCTGCG GGAGATGCAG GCGCAGGACA GGCAGCTGGC
3181 AGGGCAGCTG CTGCGGCTGC GGGCCCAGCT GCACCGACTG AAGATGGACC AAGCCTGTCA
3241 CCTGCACCAG GAGCTGCTGG ATGAGGCCGA GCTGGAGCTG GAGCTGGAGC CCGGGGCCGG
3301 CCTAGCCCTG GCCCCGCTGC TGCGGCACCT GGGCCTCACG CGCATGAACA TCAGCGCCCG
3361 GCGCTTCACC CTCTGCCACC ATCACCATCA CCATTGAAAC CCAGCTTTCT TGTACAAAGT
3421 GGTTCGATGG CCGCAGGTAA GCCAGCCCAG GCCTCGCCCT CCAGCTCAAG GCGGGACAGG
3481 TGCCCTAGAG TAGCCTGCAT CCAGGGACAG GCCCCAGCCG GGTGCTGACA CGTCCACCTC
3541 CATCTCTTCC TCAGGTCTGC CCGGGTGGCA TCCCTGTGAC CCCTCCCCAG TGCCTCTCCT
3601 GGTCTGTGAA GGTGCTACTC CAGTGCCCAC CAGCCTTGTC CTAATAAAAT TAAGTTGCAT
3661 CATTTTGTTT GACTAGGTGT CCTTGTATAA TATTATGGGG TGGAGGCGGG TGGTATGGAG
3721 CAAGGGGGCC AAGTTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC
3781 ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA
3841 CTCATCAATG TATCTTATCA TGTCTGGATC CGCTTCAGGC ACCGGGCTTG CGGGTCATGC
3901 ACCAGGTGCG CGGTCCTTCG GGCACCTCGA CGTCGGCGGT GACGGTGAAG CCGAGCCGCT
3961 CGTAGAAGGG GAGGTTGCGG GGCGCGGAGG TCTCCAGGAA GGCGGGCACC CCGGCGCGCT
4021 CGGCCGCCTC CACTCCGGGG AGCACGACGG CGCTGCCAG ACCCTTGCCC TGGTGGTCGG
4081 GCGAGACGCC GACGGTGGCC AGGAACCACG CGGGCTCCTT GGGCCGGTGC GGCGCCAGGA

16/30

4141 GGCCTTCCAT CTGTTGCTGC GCGGCCAGCC TGGAACCGCT CAACTCGGCC ATGCGCGGGC
4201 CGATCTCGGC GAACACCGCC CCCGCTTCGA CGCTCTCCGG CGTGGTCCAG ACCGCCACCG
4261 CGGCGCCGTC GTCCGCGACC CACACCTTGC CGATGTCGAG CCCGACGCGC GTGAGGAAGA
4321 GTTCTTGCAg CTCGGTGACC CGCTCGATGT GGCGGTCCGG GTCGACGGTG TGGCGCGTGG
4381 CGGGGTAGTC GGCGAACGCG GCGGCGAGGG TGCGTACGGC CCGGGGGACG TCGTCGCGGG
4441 TGGCGAGGCG CACCGTGGGC TTGTACTCGG TCATGGTGGC CTGCAGAGTC GCTCTGTGTT
4501 CGAGGCCACA CGCGTCACCT TAATATGCGA AGTGGACCTG GGACCGCGCC GCCCCGACTG
4561 CATCTGCGTG TTTTCGCCAA TGACAAGACG CTGGGCGGGG TTTGTGTCAT CATAGAACTA
4621 AAGACATGCA AATATATTTT TTCCGGGGAC ACCGCCAGCA AACGCGAGCA ACGGGCCACG
4681 GGGATGAAGC AGCTGCGCCA CTCCCTGAAG ATCCCCCTTA TTAACCCTAA ACGGGTAGCA
4741 TATGCTTCCC GGGTAGTAGT ATATACTATC CAGACTAACC CTAATTCAAT AGCATATGTT
4801 ACCCAACGGG AAGCATATGC TATCGAATTA GGGTTAGTAA AAGGGTCCTA AGGAACAGCG
4861 ATCTGGATAG CATATGCTAT CCTAATCTAT ATCTGGGTAG CATATGCTAT CCTAATCTAT
4921 ATCTGGGTAG CATAGGCTAT CCTAATCTAT ATCTGGGTAG CATATGCTAT CCTAATCTAT
4981 ATCTGGGTAG TATATGCTAT CCTAATTTAT ATCTGGGTAG CATAGGCTAT CCTAATCTAT
5041 ATCTGGGTAG CATATGCTAT CCTAATCTAT ATCTGGGTAG TATATGCTAT CCTAATCTGT
5101 ATCCGGGTAG CATATGCTAT CCTCATGCAT ATACAGTCAG CATATGATAC CCAGTAGTAG
5161 AGTGGGAGTG CTATCCTTTG CATATGCCGC CACCTCCCAA GGAGATCCGC ATGTCTGATT
5221 GCTCACCAGG TAAATGTGCG TAATGTTTTT CAACGCGAGA AGGTGTTGAG CGCGGAGCTG
5281 AGTGACGTGA CAACATGGGT ATGCCCAATT GCCCATGTT GGGAGGACGA AAATGGTGAC
5341 AAGACAGATG GCCAGAAATA CACCAACAGC ACGCATGATG TCTACTGGGG ATTTATTCTT
5401 TAGTGCGGGG GAATACACGG CTTTTAATAC GATTGAGGGC GTCTCCTAAC AAGTTACATC
5461 ACTCCTGCCC TTCCTCACCC TCATCTCCAT CACCTCCTTC ATCTCCGTCA TCTCCGTCAT
5521 CACCCTCCGC GGCAGCCCCT TCCACCATAG GTGGAAACCA GGGAGGCAAA TCTACTCCAT
5581 CGTCAAAGCT GCACACAGTC ACCCTGATAT TGCAGGTAGG AGCGGGCTTT GTCATAACAA
5641 GGTCTTAAT CGCATCCTTC AAAACCTCAG CAAATATATG AGTTTGTAAA AAGACCATGA
5701 AATAACAGAC AATGGACTCC CTTAGCGGGC CAGGTTGTGG GCCGGGTCCA GGGGCCATTC
5761 CAAAGGGGAG ACGACTCAAT GGTGTAAGAC GACATTGTGG AATAGCAAGG GCAGTTCCTC
5821 GCCTTAGGTT GTAAAGGGAG GTCTTACTAC CTCCATATAC GAACACACCG GCGACCCAAG
5881 TTCCTTCGTC GGTAGTCCTT TCTACGTGAC TCCTAGCCAG GAGAGCTCTT AAACCTTCTG
5941 CAATGTTCTC AAATTTCTGG TTGGAACCTC CTTGACCACG ATGCTTTCCA AACCACCCTC
6001 CTTTTTTGCG CCTGCCTCCA TCACCCTGAC CCCGGGGTCC AGTGCTTGGG CCTTCTCCTG
6061 GGTCATCTGC GGGGCCCTGC TCTATCGCTC CCGGGGGCAC GTCAGGCTCA CCATCTGGGC
6121 CACCTTCTTG GTGGTATTCA AAATAATCGG CTCCCCTAC AGGGTGGAAA AATGGCCTTC
6181 TACCTGGAGG GGGCCTGCGC GGTGGAGACC CGGATGATGA TGA CTGACTA CTGGGACTCC
6241 TGGGCCTCTT TTCTCCACGT CCACGACCTC TCCCCCTGGC TCTTTCACGA CTTCCCCCCC

17/30

6301 TGGCTCTTTC ACGTCCTCTA CCCC GGCGGC CTCCTACTACC TCCTCGACCC CGGCCTCCAC
6361 TACCTCCTCG ACCCCGGCCT CCACTGCCTC CTCGACCCCG GCCTCCGGCA CCTCCTCCAG
6421 CCCCAGCACC TCCACCAGCC CCAGCTCCCC CAGCTCCAGC CCCACCAGCA CCAGCCCCCTC
6481 CAGCCCCACC AGCCCCAGCC CCTCCGGCAC CTCCTCCAGC CCCAGCACCT CCACCAGCCC
6541 CAGCTCCCCC AGCTCCAGCC CCACCAGCAC CAGCCCCTCC AGCCCCACCA GCCCCAGCCC
6601 CTCCTGTTCC ACCGTGGGTC CCTTTGCAGC CAATGCAACT TGGACGTTTT TGGGGTCTCC
6661 GGACACCATC TCTATGTCTT GGCCCTGATC CTGAGCCGCC CGGGGCTCCT GGTCTTCCGC
6721 CTCCTCGTCC TCGTCCTCTT CCCC GTCCCTC GTCCATGGTT ATCACCCCTT CTTCTTTGAG
6781 GTCCACTGCC GCCGGAGCCT TCTGGTCCAG ATGTGTCTCC CTTCTCTCCT AGGCCATTTC
6841 CAGGTCCTGT ACCTGGCCCC TCGTCAGACA TGATTACAC TAAAAGAGAT CAATAGACAT
6901 CTTTATTAGA CGACGCTCAG TGAATACAGG GAGTGCAGAC TCCTGCCCCC TCCAACAGCC
6961 CCCCCACCCT CATCCCCTTC ATGGTCGCTG TCAGACAGAT CCAGGTCTGA AAATTCCCCA
7021 TCCTCCGAAC CATCCTCGTC CTCATCACCA ATTACTCGCA GCCCGGAAAA CTCCCGCTGA
7081 ACATCCTCAA GATTTGCGTC CTGAGCCTCA AGCCAGGCCT CAAATTCCTC GTCCCCCTTT
7141 TTGCTGGACG GTAGGGATGG GGATTCTCGG GACCCCTCCT CTTCTCTTC AAGGTCACCA
7201 GACAGAGATG CTACTGGGGC AACGGAAGAA AAGCTGGGTG CGGCCTGTGA AGCTAAGATC
7261 TGTCGACATC GATGGGCGCG GGTGTACACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT
7321 TCCGCCCATT CTCCGCCTCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC
7381 GCCTCGGCCT CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTGGAGG CCTAGGCTTT
7441 TGCAAAAAGC TAATTC

18/30

Figure 13

pEAK12D IPAAA26841s-6His

```
1  GCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG
61  GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAAGTGGCT TCAGCAGAGC GCAGATACCA
121 AATACTGTCC TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG
181 CCTACATACC TCGCTCTGCT GAAGCCAGTT ACCAGTGGCT GCTGCCAGTG GCGATAAGTC
241 GTGTCTTACC GGGTTGGACT CAAGAGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA
301 ACGGGGGGTT CGTGACACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC
361 CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT
421 CCGGTAAGCG GCAGGGTTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
481 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTGTGA
541 TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCAAGCTA GAGTTTAAAC
601 TTGACAGATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAAAGTAT
661 GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT
721 TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCA GAAGATCACT TGGGTGCGCG
781 AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA
841 AGAACGTTTC CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG
901 TATTGATGCC GGGCAAGAGC AACTCGGTCT CCGCATACAC TATTCTCAGA ATGACTTGGT
961 TGAATACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG
1021 CAGTGCTGCC ATAACCATGA GTGATAACAC TCGGGCCAAC TTACTTCTGA CAACTATCGG
1081 AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA
1141 TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC
1201 TGTAGCAATG GCAACAACGT TGCGAAAACCT ATTAAGTGGC GAACTACTTA CTCTAGCTTC
1261 CCGGCAACAA CTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC
1321 GGCATTCCG GCTGGCTGGT TTATTGCTGA TAAATCAGGA GCCGGTGAGC GTGGGTCACG
1381 CGGTATCATT GCAGCACTGG GGCCGGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC
1441 TACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC
1501 ACTGATTAAG CATTGGTAAG GATAAATTTT TGGTAAGGAG GACACGTATG GAAGTGGGCA
1561 AGTTGGGGAA GCCGTATCCG TTGCTGAATC TGGCATATGT GGGAGTATAA GACGCGCAGC
1621 GTCGCATCAG GCATTTTTTT CTGCGCCAAT GCAAAAAGGC CATCCGTCAG GATGGCCTTT
1681 CGGCATAACT AGTGAGGCTC CGGTGCCCCG CAGTGGGCAG AGCGCACATC GCCCACAGTC
1741 CCCGAGAAGT TGGGGGGAGG GGTCGGCAAT TGAACCGGTG CCTAGAGAAG GTGGCGCGGG
1801 GTAAACTGGG AAAGTGATGT CGTGTAAGTG CTCCGCCTTT TTCCCGAGGG TGGGGGAGAA
1861 CCGTATATAA GTGCAGTAGT CGCCGTGAAC GTTCTTTTTT GCAACGGGTT TGCCGCCAGA
1921 ACACAGGTAA GTGCCGTGTG TGGTTCCCGC GGGCCTGGCC TCTTTACGGG TTATGGCCCT
```


19/30

1981 TCGGTGCCTT GAATTACTTC CACCTGGCTG CAGTACGTGA TTCTTGATCC CGAGCTTCGG
2041 GTTGAAGTG GGTGGGAGAG TTCGAGGCCT TGCCTTAAG GAGCCCCCTC GCCTCGTGCT
2101 TGAGTTGAGG CCTGGCCTGG GCGCTGGGGC CGCCGCGTGC GAATCTGGTG GCACCTTCGC
2161 GCCTGTCTCG CTGCTTTCGA TAAGTCTCTA GCCATTTAAA ATTTTGTATG ACCTGCTGCG
2221 ACGCTTTTTT TCTGGCAAGA TAGTCTTGTA AATGCGGGCC AAGACGATCT GCACACTGGT
2281 ATTCGGTTT TTGGGGCCGC GGGCGGCGAC GGGGCCCGTG CGTCCCAGCG CACATGCATG
2341 TTCGGCGAGG CGGGGCCTGC GAGCGCGGCC ACCGAGAATC GGACGGGGGT AGTCTCAAGC
2401 TGGCCGGCCT GCTCTGGTGC CTGGCCTCGC GCCGCCGTGT ATCGCCCCGC CCTGGGCGGC
2461 AAGGCTGGGA GCTCAAAATG GAGGACGCGG CGCTCGGGAG AGCGGGCGGG TGAGTCACCC
2521 ACACAAAGGA AAAGGGCCTT TCCGTCCTCA GCCGTCGCTT CATGTGACTC CACGGAGTAC
2581 CGGGCGCCGT CCAGGCACCT CGATTAGTTC TCGAGCTTTT GGAGTACGTC GTCTTTAGGT
2641 TGGGGGGAGG GGTTTTATGC GATGGAGTTT CCCACACTG AGTGGGTGGA GACTGAAGTT
2701 AGGCCAGCTT GGCACCTGAT GTAATTCTCC TTGGAATTTG CCCTTTTGA GTTTGGATCT
2761 TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAATTAATA CGACTCACTA TAGGGAGACT
2821 TCTTTCTCCC ATTTCAGGTG TCGTAAGCTA TCAAACAAGT TTGTACAAA AAGCAGGCTT
2881 CGCCACCATG GACTCCGCCC TTGAGTGGCT CCGACGGGAG CTGCGGGAGA TGCAGGCGCA
2941 GGACAGGCAG CTGGCAGGGC AGCTGCTGCG GCTGCGGGCC CAGCTGCACC GACTGAAGAT
3001 GGACCAAGCC TGTCACCTGC ACCAGGAGCT GCTGGATGAG GCCGAGCTGG AGCTGGAGCT
3061 GGAGCCCCGGG GCCGGCCTAG CCCTGGCCCC GCTGCTGCGG CACCTGGGCC TCACGCGCAT
3121 GAACATCAGC GCCC GGCGCT TCACCCTCTG CCACCATCAC CATCACCATT GAAACCCAGC
3181 TTTCTTGTAC AAAGTGGTTC GATGGCCGCA GGTAAGCCAG CCCAGGCCTC GCCCTCCAGC
3241 TCAAGGCGGG ACAGGTGCCC TAGAGTAGCC TGCATCCAGG GACAGGCCCC AGCCGGGTGC
3301 TGACACGTCC ACCTCCATCT CTCCTCAGG TCTGCCCCGG TGGCATCCCT GTGACCCCTC
3361 CCCAGTGCCT CTCCTGGTCG TGGAAGGTGC TACTCCAGTG CCCACCAGCC TTGTCCTAAT
3421 AAAATTAAGT TGCATCATTT TGTTTACTA GGTGTCCTTG TATAATATTA TGGGGTGGAG
3481 GCGGGTGGTA TGGAGCAAGG GGCCCAAGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC
3541 AAATAAAGCA ATAGCATCAC AAATTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT
3601 TGTGGTTTGT CCAAACATCAT CAATGTATCT TATCATGTCT GGATCCGCTT CAGGCACCGG
3661 GCTTGCGGGT CATGCACCAG GTGCGCGGTC CTTGCGGCAC CTCGACGTCG GCGGTGACGG
3721 TGAAGCCGAG CCGCTCGTAG AAGGGGAGGT TGCGGGGCGC GGAGGTCTCC AGGAAGGCGG
3781 GCACCCCGGC GCGCTCGGCC GCCTCCACTC CGGGGAGCAC GACGGCGCTG CCCAGACCCT
3841 TGCCCTGGTG GTCGGGCGAG ACGCCGACGG TGGCCAGGAA CCACGCGGGC TCCTTGGGCC
3901 GGTGCGGCGC CAGGAGGCCT TCCATCTGTT GCTGCGCGGC CAGCCTGGAA CCGCTCAACT
3961 CGGCCATGCG CGGGCCGATC TCGGCGAACA CCGCCCCCGC TTCGACGCTC TCCGGCGTGG
4021 TCCAGACCGC CACCGCGGCG CCGTCGTCCG CGACCCACAC CTTGCCGATG TCGAGCCCGA
4081 CGCGCGTGAG GAAGAGTTCT TGCAGCTCGG TGACCCGCTC GATGTGGCGG TCCGGGTCGA

20/30

4141 CGGTGTGGCG CGTGGCGGGG TAGTCGGCGA ACGCGGCGGC GAGGGTGCGT ACGGCCCGGG
4201 GGACGTCGTC GCGGGTGGCG AGGCGCACCG TGGGCTTGTA CTCGGTCATG GTGGCCTGCA
4261 GAGTCGCTCT GTGTTCGAGG CCACACGCGT CACCTTAATA TGCGAAGTGG ACCTGGGACC
4321 GCGCCGCCCC GACTGCATCT GCGTGTTTTT GCCAATGACA AGACGCTGGG CGGGGTTTGT
4381 GTCATCATAG AACTAAAGAC ATGCAAATAT ATTTCTTCCG GGGACACCGC CAGCAAACGC
4441 GAGCAACGGG CCACGGGGAT GAAGCAGCTG CGCCACTCCC TGAAGATCCC CCTTATTAAC
4501 CCTAAACGGG TAGCATATGC TTCCCGGGTA GTAGTATATA CTATCCAGAC TAACCCTAAT
4561 TCAATAGCAT ATGTTACCCA ACGGGAAGCA TATGCTATCG AATTAGGGTT AGTAAAAGGG
4621 TCCTAAGGAA CAGCGATCTG GATAGCATAT GCTATCCTAA TCTATATCTG GGTAGCATAT
4681 GCTATCCTAA TCTATATCTG GGTAGCATAG GCTATCCTAA TCTATATCTG GGTAGCATAT
4741 GCTATCCTAA TCTATATCTG GGTAGTATAT GCTATCCTAA TTTATATCTG GGTAGCATAG
4801 GCTATCCTAA TCTATATCTG GGTAGCATAT GCTATCCTAA TCTATATCTG GGTAGTATAT
4861 GCTATCCTAA TCTGTATCCG GGTAGCATAT GCTATCCTCA TGCATATACA GTCAGCATAT
4921 GATACCCAGT AGTAGAGTGG GAGTGCTATC CTTTGCTATG GCCGCCACCT CCCAAGGAGA
4981 TCCGCATGTC TGATTGCTCA CCAGGTAAAT GTCGCTAATG TTTTCCAACG CGAGAAGGTG
5041 TTGAGCGCGG AGCTGAGTGA CGTGACAACA TGGGTATGCC CAATTGCCCC ATGTTGGGAG
5101 GACGAAAATG GTGACAAGAC AGATGGCCAG AAATACACCA ACAGCACGCA TGATGTCTAC
5161 TGGGGATTTA TTCTTTAGTG CGGGGGAATA CACGGCTTTT AATACGATTG AGGGCGTCTC
5221 CTAACAAGTT ACATCACTCC TGCCCTTCCT CACCCTCATC TCCATCACCT CCTTCATCTC
5281 CGTCATCTCC GTCATCACCC TCCGCGGCAG CCCCTTCCAC CATAGGTGGA AACCAGGGAG
5341 GCAAATCTAC TCCATCGTCA AAGCTGCACA CAGTCACCCT GATATTGCAG GTAGGAGCGG
5401 GCTTTGTCAT AACAAGGTCC TTAATCGCAT CCTTCAAAC CTCAGCAAAT ATATGAGTTT
5461 GTAAAAAGAC CATGAAATAA CAGACAATGG ACTCCCTTAG CGGGCCAGGT TGTGGGCCGG
5521 GTCCAGGGGC CATTCCAAAG GGGAGACGAC TCAATGGTGT AAGACGACAT TGTGGAATAG
5581 CAAGGGCAGT TCCTCGCCTT AGGTTGTAAA GGGAGGTCTT ACTACCTCCA TATACGAACA
5641 CACCGGCGAC CCAAGTTCCT TCGTCGGTAG TCCTTTCTAC TGACTCCTA GCCAGGAGAG
5701 CTCTTAAACC TTCTGCAATG TTCTCAAATT TCGGGTTGGA ACCTCCTTGA CCACGATGCT
5761 TTCCAAACCA CCCTCCTTTT TTGCGCCTGC CTCCATCACC CTGACCCCGG GGTCCAGTGC
5821 TTGGGCCTTC TCCTGGGTCA TCTGCGGGGC CCTGCTCTAT CGCTCCCGGG GGCACGTCAG
5881 GCTCACCATC TGGGCCACCT TCTTGGTGGT ATTCAAATA ATCGGCTTCC CCTACAGGGT
5941 GGAAAAATGG CCTTCTACCT GGAGGGGGCC TGC GCGGTGG AGACCCGGAT GATGATGACT
6001 GACTACTGGG ACTCCTGGGC CTCTTTTCTC CACGTCCACG ACCTCTCCCC CTGGCTCTTT
6061 CACGACTTCC CCCCCTGGCT CTTTCACGTC CTCTACCCCG GCGGCCTCCA CTACCTCCTC
6121 GACCCCGGCC TCCACTACCT CCTCGACCCC GGCCTCCACT GCCTCCTCGA CCCC GGCCCTC
6181 CGGCACCTCC TCCAGCCCCA GCACCTCCAC CAGCCCCAGC TCCCCCAGCT CCAGCCCCAC
6241 CAGCACCAGC CCCTCCAGCC CCACCAGCCC CAGCCCCTCC GGCACCTCCT CCAGCCCCAG

21/30

6301 CACCTCCACC AGCCCCAGCT CCCCCAGCTC CAGCCCCACC AGCACCAGCC CCTCCAGCCC
6361 CACCAGCCCC AGCCCCTCCT GTTCCACCGT GGGTCCCTTT GCAGCCAATG CAACTTGGAC
6421 GTTTTTGGGG TCTCCGGACA CCATCTCTAT GTCTTGGCCC TGATCCTGAG CCGCCCGGGG
6481 CTCCTGGTCT TCCGCCTCCT CGTCCTCGTC CTCTTCCCCG TCCTCGTCCA TGGTTATCAC
6541 CCCCTCTTCT TTGAGGTCCA CTGCCGCCGG AGCCTTCTGG TCCAGATGTG TCTCCCTTCT
6601 CTCCTAGGCC ATTTCCAGGT CCTGTACCTG GCCCCTCGTC AGACATGATT CACACTAAAA
6661 GAGATCAATA GACATCTTTA TTAGACGACG CTCAGTGAAT ACAGGGAGTG CAGACTCCTG
6721 CCCCTCCAA CAGCCCCCCC ACCCTCATCC CCTTCATGGT CGCTGTCAGA CAGATCCAGG
6781 TCTGAAAATT CCCCATCCTC CGAACCATCC TCGTCCTCAT CACCAATTAC TCGCAGCCCG
6841 GAAAACTCCC GCTGAACATC CTCAAGATTT GCGTCCTGAG CCTCAAGCCA GGCCTCAAAT
6901 TCCTCGTCCC CCTTTTTGCT GGACGGTAGG GATGGGGATT CTCGGGACCC CTCCTCTTCC
6961 TCTTCAAGGT CACCAGACAG AGATGCTACT GGGGCAACGG AAGAAAAGCT GGGTGCGGCC
7021 TGTGAAGCTA AGATCTGTCG ACATCGATGG GCGCGGGTGT ACACTCCGCC CATCCCGCCC
7081 CTA ACTCCGC CCAGTTCCGC CCATTCTCCG CCTCATGGCT GACTAATTTT TTTTATTTAT
7141 GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT
7201 GGAGGCCTAG GCTTTTGCAA AAAGCTAATT C

22/30

Figure 14

pEAK12D – sigptdIPAAA26841s-6His

```
1  GCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG
61  GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACCTGGCT TCAGCAGAGC GCAGATACCA
121 AATACTGTCC TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG
181 CCTACATACC TCGCTCTGCT GAAGCCAGTT ACCAGTGGCT GCTGCCAGTG GCGATAAGTC
241 GTGTCTTACC GGGTTGGACT CAAGAGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA
301 ACGGGGGGTT CGTGCACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC
361 CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT
421 CCGGTAAGCG GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
481 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTTGTGA
541 TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCAAGCTA GAGTTTAAAC
601 TTGACAGATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAAAGTAT
661 GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT
721 TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCA GAAGATCACT TGGGTGCGCG
781 AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA
841 AGAACGTTTC CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG
901 TATTGATGCC GGGCAAGAGC AACTCGGTCT CCGCATAAC TATTCTCAGA ATGACTTGGT
961 TGAATACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG
1021 CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTA CTCTGA CAACTATCGG
1081 AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA
1141 TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC
1201 TG TAGCAATG GCAACAACGT TGC GAAA ACT ATTA ACTGGC GAACTACTTA CTCTAGCTTC
1261 CCGGCAACAA CTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC
1321 GGC ACTTCCG GCTGGCTGGT TTATTGCTGA TAAATCAGGA GCCGGTGAGC GTGGGTCACG
1381 CGGTATCATT GCAGCACTGG GGCCGGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC
1441 TACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC
1501 ACTGATTAAG CATTGGTAAG GATAAATTTT TGGTAAGGAG GACACGTATG GAAGTGGGCA
1561 AGTTGGGGAA GCCGTATCCG TTGCTGAATC TGGCATATGT GGGAGTATAA GACGCGCAGC
1621 GTCGCATCAG GCATTTTTTT CTGCGCCAAT GCAAAAAGGC CATCCGTCAG GATGGCCTTT
1681 CGGCATAACT AGTGAGGCTC CGGTGCCCGT CAGTGGGCAG AGCGCACATC GCCCACAGTC
1741 CCCGAGAAGT TGGGGGGAGG GGTCGGCAAT TGAACCGGTG CCTAGAGAAG GTGGCGCGGG
1801 GTAAACTGGG AAAGTGATGT CGTG TACTGG CTCCGCCTTT TTCCCGAGGG TGGGGGAGAA
```


23/30

1861 CCGTATATAA GTGCAGTAGT CGCCGTGAAC GTTCTTTTTT GCAACGGGTT TGCCGCCAGA
1921 ACACAGGTAA GTGCCGTGTG TGGTTCCCGC GGGCCTGGCC TCTTTACGGG TTATGGCCCT
1981 TGCGTGCCTT GAATTACTTC CACCTGGCTG CAGTACGTGA TTCTTGATCC CGAGCTTCGG
2041 GTTGGAAGTG GGTGGGAGAG TTCGAGGCCT TGCCTTAAG GAGCCCCTTC GCCTCGTGCT
2101 TGAGTTGAGG CCTGGCCTGG GCGCTGGGGC CGCCGCGTGC GAATCTGGTG GCACCTTCGC
2161 GCCTGTCTCG CTGCTTTCGA TAAGTCTCTA GCCATTTAAA ATTTTGTATG ACCTGCTGCG
2221 ACGCTTTTTT TCTGGCAAGA TAGTCTTGTA AATGCGGGCC AAGACGATCT GCACACTGGT
2281 ATTCGGTTT TTGGGGCCGC GGGCGGCGAC GGGGCCCGTG CGTCCCAGCG CACATGCATG
2341 TTCGGCGAGG CGGGGCCTGC GAGCGCGGCC ACCGAGAATC GGACGGGGGT AGTCTCAAGC
2401 TGGCCGGCCT GCTCTGGTGC CTGGCCTCGC GCCGCCGTGT ATCGCCCCGC CCTGGGCGGC
2461 AAGGCTGGGA GCTCAAAATG GAGGACGCGG CGCTCGGGAG AGCGGGCGGG TGAGTCACCC
2521 ACACAAAGGA AAAGGGCCTT TCCGTCCTCA GCCGTCGCTT CATGTGACTC CACGGAGTAC
2581 CGGGCGCCGT CCAGGCACCT CGATTAGTTC TCGAGCTTTT GGAGTACGTC GTCTTTAGGT
2641 TGGGGGGAGG GGTTTTATGC GATGGAGTTT CCCACACTG AGTGGGTGGA GACTGAAGTT
2701 AGGCCAGCTT GGCACCTGAT GTAATTCTCC TTGGAATTTG CCCTTTTGA GTTTGGATCT
2761 TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAATTAATA CGACTCACTA TAGGGAGACT
2821 TCTTTCTCCC ATTCAGGTG TCGTAAGCTA TCAAACAAGT TTGTACAAA AAGCAGGCTT
2881 CGCCACCATG TGTCACCAGC AGTTGGTCAT CTCTTGTTTT TCCCTGGTTT TTCTGGCATC
2941 TCCCCTCGTG GCCATAGACT CCGCCCTTGA GTGGCTCCGA CGGGAGCTGC GGGAGATGCA
3001 GGCAGCAGGAC AGGCAGCTGG CAGGGCAGCT GCTGCGGCTG CGGGCCCAGC TGCACCGACT
3061 GAAGATGGAC CAAGCCTGTC ACCTGCACCA GGAGCTGCTG GATGAGGCCG AGCTGGAGCT
3121 GGAGCTGGAG CCCGGGGCCG GCCTAGCCCT GGCCCCGCTG CTGCGGCACC TGGGCCTCAC
3181 GCGCATGAAC ATCAGCGCCC GCGCTTCAC CCTCTGCCAC CATCACCATC ACCATTGAAA
3241 CCCAGCTTTC TTGTACAAAG TGGTTCGATG GCCGCAGGTA AGCCAGCCCA GGCTCGCCC
3301 TCCAGCTCAA GGCGGGACAG GTGCCCTAGA GTAGCCTGCA TCCAGGGACA GGCCCCAGCC
3361 GGGTGCTGAC ACGTCCACCT CCATCTCTTC CTCAGGTCTG CCCGGGTGGC ATCCCTGTGA
3421 CCCCTCCCA GTGCCTCTCC TGGTCGTGGA AGGTGCTACT CCAGTGCCCA CCAGCCTTGT
3481 CCTAATAAAA TTAAGTTGCA TCATTTTGTT TGA TAGGTG TCCTTGATA ATATTATGGG
3541 GTGGAGGCGG GTGGTATGGA GCAAGGGGCC CAAGTTAACT TGTTTATTGC AGCTTATAAT
3601 GGTACAAAT AAAGCAATAG CATCACAAAT TTCACAAATA AAGCATTTTT TTA CTGCAT
3661 TCTAGTTGTG GTTTGTCCAA ACTCATCAAT GTATCTTATC ATGTCTGGAT CCGCTTCAGG
3721 CACCGGGCTT GCGGGTCATG CACGAGGTGC GCGGTCCTTC GGGCACCTCG ACGTCGGCGG
3781 TGACGGTGAA GCCGAGCCGC TCGTAGAAGG GGAGGTTGCG GGGCGCGGAG GTCTCCAGGA
3841 AGGCGGGCAC CCCGGCGCGC TCGGCCGCCT CCACTCCGGG GAGCACGACG GCGCTGCCCA
3901 GACCCTTGCC CTGGTGGTCG GCGGAGACGC CGACGGTGGC CAGGAACCAC GCGGGCTCCT
3961 TGGGCCGGTG CGGCGCCAGG AGGCCTTCCA TCTGTTGCTG CGCGGCCAGC CTGGAACCGC

24/30

4021 TCAACTCGGC CATGCGCGGG CCGATCTCGG CGAACACCGC CCCCCTTCG ACGCTCTCCG
4081 GCGTGGTCCA GACCGCCACC GCGGCGCCGT CGTCCGCGAC CCACACCTTG CCGATGTCGA
4141 GCCCGACGCG CGTGAGGAAG AGTTCTTGCA GCTCGGTGAC CCGCTCGATG TGGCGGTCCG
4201 GGTCGACGGT GTGGCGCGTG GCGGGGTAGT CGGCGAACGC GGCGGCGAGG GTGCGTACGG
4261 CCCGGGGGAC GTCGTCGCGG GTGGCGAGGC GCACCGTGGG CTTGTACTCG GTCATGGTGG
4321 CCTGCAGAGT CGCTCTGTGT TCGAGGCCAC ACGCGTCACC TTAATATGCG AAGTGGACCT
4381 GGGACCGCGC CGCCCCGACT GCATCTGCGT GTTTTCGCCA ATGACAAGAC GCTGGGCGGG
4441 GTTTGTGTCA TCATAGAACT AAAGACATGC AAATATATTT CTTCCGGGGA CACCGCCAGC
4501 AAACGCGAGC AACGGGCCAC GGGGATGAAG CAGCTGCGCC ACTCCCTGAA GATCCCCCTT
4561 ATTAACCCTA AACGGGTAGC ATATGCTTCC CGGGTAGTAG TATATACTAT CCAGACTAAC
4621 CCTAATTCAA TAGCATATGT TACCCAACGG GAAGCATATG CTATCGAATT AGGGTTAGTA
4681 AAAGGGTCCT AAGGAACAGC GATCTGGATA GCATATGCTA TCCTAATCTA TATCTGGGTA
4741 GCATATGCTA TCCTAATCTA TATCTGGGTA GCATAGGCTA TCCTAATCTA TATCTGGGTA
4801 GCATATGCTA TCCTAATCTA TATCTGGGTA GTATATGCTA TCCTAATTTA TATCTGGGTA
4861 GCATAGGCTA TCCTAATCTA TATCTGGGTA GCATATGCTA TCCTAATCTA TATCTGGGTA
4921 GTATATGCTA TCCTAATCTG TATCCGGGTA GCATATGCTA TCCTCATGCA TATACAGTCA
4981 GCATATGATA CCCAGTAGTA GAGTGGGAGT GCTATCCTTT GCATATGCCG CCACCTCCCA
5041 AGGAGATCCG CATGTCTGAT TGCTCACCAG GTAAATGTCT CTAATGTTTT CCAACGCGAG
5101 AAGGTGTTGA GCGCGGAGCT GAGTGACGTG ACAACATGGG TATGCCCAAT TGCCCCATGT
5161 TGGGAGGACG AAAATGGTGA CAAGACAGAT GGCCAGAAAT ACACCAACAG CACGCATGAT
5221 GTCTACTGGG GATTTATTCT TTAGTGCGGG GGAATACACG GCTTTTAATA CGATTGAGGG
5281 CGTCTCCTAA CAAGTTACAT CACTCCTGCC CTTCTCACC CTCATCTCCA TCACCTCCTT
5341 CATCTCCGTC ATCTCCGTCA TCACCCTCCG CGGCAGCCCC TTCCACCATA GGTGGAAACC
5401 AGGGAGGCAA ATCTACTCCA TCGTCAAAGC TGCACACAGT CACCCTGATA TTGCAGGTAG
5461 GAGCGGGCTT TGTCATAACA AGGTCCTTAA TCGCATCCTT CAAAACCTCA GCAAATATAT
5521 GAGTTTGTA AAAGACCATG AAATAACAGA CAATGGACTC CCTTAGCGGG CCAGGTTGTG
5581 GGCCGGGTCC AGGGGCCATT CCAAAGGGGA GACGACTCAA TGGTGTAAGA CGACATTGTG
5641 GAATAGCAAG GGCAGTTCCT CGCCTTAGGT TGTAAGGGGA GGTCTTACTA CCTCCATATA
5701 CGAACACACC GGCGACCCAA GTTCCTTCGT CGGTAGTCCT TTCTACGTGA CTCCTAGCCA
5761 GGAGAGCTCT TAAACCTTCT GCAATGTTCT CAAATTTCTG GTTGGAACCT CCTTGACCAC
5821 GATGCTTTCC AAACCACCCT CCTTTTTTGC GCCTGCCTCC ATCACCCTGA CCCCAGGGGTC
5881 CAGTGCTTGG GCCTTCTCCT GGGTCATCTG CGGGGCCCTG CTCTATCGCT CCCGGGGGCA
5941 CGTCAGGCTC ACCATCTGGG CCACCTTCTT GGTGGTATTC AAAATAATCG GCTTCCCCTA
6001 CAGGGTGGAA AAATGGCCTT CTACCTGGAG GGGGCCTGCG CGGTGGAGAC CCGGATGATG
6061 ATGACTGACT ACTGGGACTC CTGGGCCTCT TTTCTCCACG TCCACGACCT CTCCCCCTGG
6121 CTCTTTCACG ACTTCCCCCC CTGGCTCTTT CACGTCCTCT ACCCGGCGG CCTCCACTAC

25/30

6181 CTCCTCGACC CCGGCCTCCA CTACCTCCTC GACCCCGGCC TCCACTGCCT CCTCGACCCC
6241 GGCCTCCGGC ACCTCCTCCA GCCCCAGCAC CTCCACCAGC CCCAGCTCCC CCAGCTCCAG
6301 CCCCACCAGC ACCAGCCCCT CCAGCCCCAC CAGCCCCAGC CCCTCCGGCA CCTCCTCCAG
6361 CCCCAGCACC TCCACCAGCC CCAGCTCCCC CAGCTCCAGC CCCACCAGCA CCAGCCCCTC
6421 CAGCCCCACC AGCCCCAGCC CCTCCTGTTC CACCGTGGGT CCCTTTGCAG CCAATGCAAC
6481 TTGGACGTTT TTGGGGTCTC CGGACACCAT CTCTATGTCT TGGCCCTGAT CCTGAGCCGC
6541 CCGGGGCTCC TGGTCTTCCG CCTCCTCGTC CTCGTCCTCT TCCCCGTCCT CGTCCATGGT
6601 TATCACCCCC TCTTCTTTGA GGTCCACTGC CGCCGGAGCC TTCTGGTCCA GATGTGTCTC
6661 CCTTCTCTCC TAGGCCATTT CCAGGTCCTG TACCTGGCCC CTCGTCAGAC ATGATTCACA
6721 CTAAAAGAGA TCAATAGACA TCTTTATTAG ACGACGCTCA GTGAATACAG GGAGTGCAGA
6781 CTCCTGCCCC CTCCAACAGC CCCCCACCC TCATCCCCTT CATGGTCGCT GTCAGACAGA
6841 TCCAGGTCTG AAAATTCCCC ATCCTCCGAA CCATCCTCGT CCTCATCACC AATTACTCGC
6901 AGCCCGGAAA ACTCCCGCTG AACATCCTCA AGATTTGCGT CCTGAGCCTC AAGCCAGGCC
6961 TCAAATTCCT CGTCCCCCTT TTTGCTGGAC GGTAGGGATG GGGATTCTCG GGACCCCTCC
7021 TCTTCCTCTT CAAGGTCACC AGACAGAGAT GCTACTGGGG CAACGGAAGA AAAGCTGGGT
7081 GCGGCCTGTG AAGCTAAGAT CTGTCGACAT CGATGGGCGC GGGTGTACAC TCCGCCCATC
7141 CCGCCCCTAA CTCCGCCCAG TTCCGCCCAT TCTCCGCCTC ATGGCTGACT AATTTTTTTT
7201 ATTTATGCAG AGGCCGAGGC CGCCTCGGCC TCTGAGCTAT TCCAGAAGTA GTGAGGAGGC
7261 TTTTTTGGAG GCCTAGGCTT TTGCAAAAAG CTAATTC

26/30

Figure 15 NCBI-nr

Query= insp035 (163 letters)

Database: All non-redundant GenBank CDS

translations+PDB+SwissProt+PIR+PRF

1,242,768 sequences; 395,571,179 total letters

	Score	E
	(bits)	Value
Sequences producing significant alignments:		
ref NP_116037.1 hypothetical protein MGC10820 [Homo sapiens] >g...	148	3e-35
ref XP_131704.2 similar to SEC protein [Mus musculus] >gi 25021...	132	2e-30
sp P17257 SEC_HUMAN SEC protein >gi 69029 pir TVHUSE transformi...	123	1e-27
gb AAL89663.1 AF411956_4 hypothetical protein [Takifugu rubripes]	116	1e-25
ref XP_127784.1 similar to hypothetical protein MGC10820 [Homo ...	94	9e-19

>ref|NP_116037.1| hypothetical protein MGC10820 [Homo sapiens]

gb|AAH04269.1|AAH04269 Unknown (protein for MGC:10820) [Homo sapiens]

Length = 74 Score = 148 bits (373), Expect = 3e-35

Identities = 74/74 (100%), Positives = 74/74 (100%)

Query: 90 MQAQDRQLAGQLRLRLRAQLHRLKMDQACHLHQELLDEAELELELEPGAGLALAPLLRH LG 149

MQAQDRQLAGQLRLRLRAQLHRLKMDQACHLHQELLDEAELELELEPGAGLALAPLLRH LG

Sbjct: 1 MQAQDRQLAGQLRLRLRAQLHRLKMDQACHLHQELLDEAELELELEPGAGLALAPLLRH LG 60

Query: 150 LTRMNISARRFTLC 163

LTRMNISARRFTLC

Sbjct: 61 LTRMNISARRFTLC 74

>sp|P17257|SEC_HUMAN SEC protein

pir||TVHUSE transforming protein sec - human

emb|CAA36502.1| SEC protein (AA 1-109) [Homo sapiens]

Length = 109 Score = 123 bits (308), Expect = 1e-27

Identities = 61/72 (84%), Positives = 66/72 (90%)

Query: 90 MQAQDRQLAGQLRLRLRAQLHRLKMDQACHLHQELLDEAELELELEPGAGLALAPLLRH LG 149

M+AQDRQLAGQ +RLRA+LHRLK+DQ CHLHQELLDEAELE+ELE G GL LAP LRHLG

Sbjct: 1 MRAQDRQLAGQPVRLRLRLHRLKVDQVCHLHQELLDEAELEMELESGTGLPLAPPLRH LG 60

Query: 150 LTRMNISARRFT 161

LTRMNISARRFT

Sbjct: 61 LTRMNISARRFT 72

27/30

Figure 16

NCBI-month-aa/NCBI-month-nt

Query= insp035

(163 letters)

Database: NCBI: Rolling month (30 days) of new/revised protein
sequences

45,458 sequences; 18,189,306 total letters

Searching.....done

	Score	E
Sequences producing significant alignments:	(bits)	Value
ref XP_131704.2 similar to SEC protein [Mus musculus] >gi 25021...	132	2e-31
ref NP_055540.1 START domain containing 8; KIAA0189 gene produc...	35	0.027
ref XP_135732.1 similar to Peripherin [Mus musculus] >gi 250462...	33	0.13
ref NP_731948.1 CG31306-PA [Drosophila melanogaster] >gi 231712...	32	0.23
emb CAB05840.2 Hypothetical protein ZK131.11a [Caenorhabditis e...	32	0.30

>ref|XP_131704.2| similar to SEC protein [Mus musculus]
 ref|XP_204036.1| similar to SEC protein [Mus musculus]
 gb|AAH30183.1| Unknown (protein for MGC:29254) [Mus musculus]
 Length = 74

Score = 132 bits (331), Expect = 2e-31

Identities = 65/74 (87%), Positives = 69/74 (92%)

Query: 90 MQAQDRQLAGQLLRLRAQLHRLKMDQACHLHQELLDEAELELELEPGAGLALAPLLRHLG 149
 M+AQDRQLAGQLLRLRA+LHRLK+DQ CHLHQELLDEAELE+ELE G GL LAP LRHLG
 Sbjct: 1 MRAQDRQLAGQLLRLRARLHRLKVDQVCHLHQELLDEAELEMELESGTGLPLAPPLRHLG 60

Query: 150 LTRMNISARRFTLC 163

LTRMNISARRFTLC

Sbjct: 61 LTRMNISARRFTLC 74

28/30

Figure 17

NCBI-nt

Query= insp035 (163 letters)

Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, GSS,
or phase 0, 1 or 2 HTGS sequences)

1,469,831 sequences; 7,238,625,236 total letters

Searching.....done

	Score	E
Sequences producing significant alignments:	(bits)	Value
ref NM_032648.1 Homo sapiens hypothetical protein MGC10820 (MGC...	326	4e-88
gb BC004269.1 BC004269 Homo sapiens, clone MGC:10820 IMAGE:36137...	326	4e-88
gb BC030183.1 Mus musculus, clone MGC:29254 IMAGE:5054849, mRNA...	278	1e-73
ref XM_131704.1 Mus musculus similar to SEC protein (LOC230766)...	277	3e-73
ref XM_204036.1 Mus musculus similar to SEC protein (LOC277661)...	277	3e-73

>ref|NM_032648.1| Homo sapiens hypothetical protein MGC10820 (MGC10820), mRNA

Length = 959 Score = 326 bits (836), Expect = 4e-88

Identities = 163/163 (100%), Positives = 163/163 (100%)

Frame = +1

Query: 1 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 60

MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA

Sbjct: 190 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 369

Query: 61 KPGPGGPGDICGFDSMDSALEWLRRELREMQAQRQLAGQLLRLRAQLHRLKMDQACHLH 120

KPGPGGPGDICGFDSMDSALEWLRRELREMQAQRQLAGQLLRLRAQLHRLKMDQACHLH

Sbjct: 370 KPGPGGPGDICGFDSMDSALEWLRRELREMQAQRQLAGQLLRLRAQLHRLKMDQACHLH 549

Query: 121 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 163

QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC

Sbjct: 550 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 678

>gb|BC004269.1|BC004269 Homo sapiens, clone MGC:10820 IMAGE:3613742, mRNA,
complete cds

Length = 959

Score = 326 bits (836), Expect = 4e-88

29/30

Identities = 163/163 (100%), Positives = 163/163 (100%)

Frame = +1

Query: 1 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 60
MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA
Sbjct: 190 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 369

Query: 61 KPGPGGPGDICGFDSDMSALEWLRRELREMQAQDRQLAGQLRLRLRAQLHRLKMDQACHLH 120
KPGPGGPGDICGFDSDMSALEWLRRELREMQAQDRQLAGQLRLRLRAQLHRLKMDQACHLH
Sbjct: 370 KPGPGGPGDICGFDSDMSALEWLRRELREMQAQDRQLAGQLRLRLRAQLHRLKMDQACHLH 549

Query: 121 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 163
QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC
Sbjct: 550 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 678

30/30

Figure 18

NCBI-est

>gb|BM014200.1|BM014200 603639895F1 NIH_MGC_87 Homo sapiens cDNA clone
IMAGE:5416127 5'.

Length = 776

Score = 326 bits (836), Expect = 1e-88

Identities = 163/163 (100%), Positives = 163/163 (100%)

Frame = +2

Query: 1 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 60
MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA
Sbjct: 122 MSLGLLKFQAVGEEDEEDEEGESLDSVKALTAKLQLQTRRPSYLEWTAQVQSQAARRAQA 301

Query: 61 KPGPGGPGDICGFDSDMSALEWLRRELREMQAQRQLAGQLRLRAQLHRLKMDQACHLH 120
KPGPGGPGDICGFDSDMSALEWLRRELREMQAQRQLAGQLRLRAQLHRLKMDQACHLH
Sbjct: 302 KPGPGGPGDICGFDSDMSALEWLRRELREMQAQRQLAGQLRLRAQLHRLKMDQACHLH 481

Query: 121 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 163
QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC
Sbjct: 482 QELLDEAELELELEPGAGLALAPLLRHLGLTRMNISARRFTLC 61